86 results on '"Borrow, R"'
Search Results
2. Lower risk of invasive meningococcal disease during pregnancy: national prospective surveillance in England, 2011-2014.
- Author
-
Parikh, Sydel R, Borrow, Ray, Ramsay, Mary E, Ladhani, Shamez N, Parikh, S R, Borrow, R, Ramsay, M E, and Ladhani, S N
- Subjects
COMMUNICABLE disease epidemiology ,LONGITUDINAL method ,NEISSERIA meningitidis ,PREGNANCY complications ,PUBLIC health surveillance ,QUESTIONNAIRES ,DISEASE incidence ,SEROTYPES - Abstract
Objective: To describe cases of invasive meningococcal disease (IMD) in women of childbearing age and to estimate the disease incidence and relative risk of IMD in pregnant compared with non-pregnant women.Design: Prospective enhanced national surveillance for IMD.Setting: England.Population: Women of reproductive age (15-44 years) with laboratory-confirmed IMD.Methods: Public Health England conducts enhanced national surveillance for IMD in England. Laboratory-confirmed cases are followed up with postal questionnaires to general practitioners. All cases confirmed in women of reproductive age from 1 January 2011 to 31 December 2014 were included.Main Outcome Measures: Annual IMD incidence and relative risk of IMD in pregnant compared with non-pregnant women of reproductive age.Results: During the 4-year surveillance period, there were 1502 cases of IMD in females across England; of these, 310 (20.6%) cases were in women of reproductive age, including four women who were pregnant at the time of IMD confirmation (1.3%). Serogroup distribution of IMD cases in women of childbearing age was similar to the overall distribution. The four cases in otherwise healthy pregnant women were confirmed across all trimesters and all survived; one case in the first trimester had a septic miscarriage. The incidence of IMD was lower in pregnant than in non-pregnant women (0.16 compared with 0.76 per 100 000 pregnant and non-pregnant years, respectively), giving a lower risk of IMD in pregnant women (incidence rate ratio, IRR, 0.21; 95% confidence interval, 0.06-0.54).Conclusions: Pregnant women are nearly five times less likely to develop IMD compared with non-pregnant women, but the infection can be severe.Tweetable Abstract: The risk of meningococcal disease is lower in pregnant women compared with non-pregnant women; the infection can occur across all trimesters and can be severe. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
3. Reassurance of population immunity to diphtheria in England: Results from a 2021 national serosurvey.
- Author
-
Vusirikala A, Tonge S, Bell A, Linley E, Borrow R, O'Boyle S, de Lusignan S, Charlett A, Balasegaram S, and Amirthalingam G
- Subjects
- Humans, England epidemiology, Adolescent, Adult, Young Adult, Child, Child, Preschool, Aged, Middle Aged, Male, Female, Infant, Seroepidemiologic Studies, Aged, 80 and over, Diphtheria Toxoid immunology, Diphtheria Toxoid administration & dosage, Diphtheria immunology, Diphtheria prevention & control, Diphtheria epidemiology, Antibodies, Bacterial blood
- Abstract
Background: Diphtheria is rare in England because of an effective national immunisation schedule that includes 5 doses of a diphtheria-containing vaccine at 2, 3, 4 months, preschool and adolescent boosters. However, in recent years there has been a notable increase in cases due to Corynebacterium ulcerans among older adults and evidence of endemic transmission of C. diphtheriae (normally associated with travel to endemic countries). We aimed to update 2009 estimates of diphtheria immunity considering the evolving epidemiology., Methods: Residual sera collected from diagnostic laboratories and general practitioners in England in 2021 were randomly selected and tested for diphtheria antibody, to estimate proportions protected per age group. Diphtheria antibody levels were defined as susceptible (<0.01 IU/mL), basic protection (0.01-0.099 IU/mL) and full protection (≥0.1 IU/mL). Immunity estimates were standardised to the England population and compared to 2009., Results: Based on 3,745 residual sera tested, 89% (95%CI: 87%-90%) of the 2021 England population had at least basic diphtheria protection (vs. 90% [88%-92%] in 2009) and 50% (48%-52%) full protection (vs. 41% [38%-44%]). Higher antibody levels were observed in those aged 1 and under, 10-11, 12-15, 25-34 and 35-44 years compared to 2009. The largest proportion susceptible were observed in those aged 70+, 26% (21%-31%) vs 12% (7%-18%) in 2009., Conclusions: Basic diphtheria protection is comparable between 2021 and 2009. The increase in immunity in working age adults is likely due to the school leaver booster introduced in 1994. The current vaccination schedule is maintaining sufficient population immunity. However, we recommend clinicians remain vigilant to severe diphtheria outcomes in older adults, because of their observed susceptibility., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Crown Copyright © 2023. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
4. Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England.
- Author
-
Clark SA, Campbell H, Ribeiro S, Bertran M, Walsh L, Walker A, Willerton L, Lekshmi A, Bai X, Lucidarme J, Ladhani SN, and Borrow R
- Subjects
- Humans, England epidemiology, Adolescent, Child, Adult, Young Adult, Child, Preschool, Infant, Male, Female, Middle Aged, Aged, Meningococcal Vaccines administration & dosage, Pandemics, Serogroup, Infant, Newborn, COVID-19 epidemiology, COVID-19 prevention & control, Meningococcal Infections epidemiology, Meningococcal Infections prevention & control, Neisseria meningitidis, SARS-CoV-2
- Abstract
Objectives: In 2020, COVID-19 pandemic restrictions led to a major suppression of meningococcal disease in England. Here we describe the epidemiology of invasive meningococcal disease in the three years prior to the COVID-19 pandemic, and the three years immediately after the introduction of restrictions., Methods: The UK Health Security Agency conducts national meningococcal disease surveillance in England consisting of laboratory-based case confirmation with strain characterisation by culture and/or molecular detection, as well as clinical follow-up of all cases., Results: In the pre-pandemic period, 554-742 IMD cases were laboratory-confirmed per year. MenB caused 57.2% of cases, followed by MenW (22.7%), MenY (10.6%) and MenC (7.7%). The introduction of restrictions in late March 2020 led to a 73% reduction in IMD. After the removal of restrictions in 2021, a resurgence in MenB was observed, primarily in teenagers and young adults. During the following winter period (2022/23), MenB disease increased to the highest level since 2012 with cases rising across multiple age groups, however, cases in young children eligible for MenB vaccination remained lower than prior to the pandemic. MenACWY cases remained very low throughout the pandemic period., Conclusions: Once pandemic restrictions in England were removed, MenB quickly rebounded- initially driven by a resurgence in teenagers/young adults, but later among other age groups. MenACWY cases remain very low due to the protection afforded by the adolescent MenACWY conjugate vaccine programme., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AL, AW, JL, LWa, LWi, RB, SAC and XB perform contract research on behalf of UK Health Security Agency for GlaxoSmithKline, Pfizer, and Sanofi Pasteur but receive no personal remuneration. SNL performs contract research on behalf of UK Health Security Agency and St. George’s University of London for vaccine manufacturers but receives no personal remuneration., (Crown Copyright © 2023. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
5. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study.
- Author
-
Mensah AA, Campbell H, Clark SA, Ribeiro S, Lucidarme J, Bai X, Borrow R, and Ladhani SN
- Subjects
- Infant, Humans, Child, Prospective Studies, Serogroup, Vaccination, England, Vaccines, Combined, Disease Progression, Meningococcal Infections epidemiology, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B
- Abstract
Background: In 2015, the UK included 4CMenB, a multi-component, recombinant protein-based vaccine against meningococcal serogroup B (MenB) disease, in the national infant immunisation programme. We aimed to assess the effect of 4CMenB vaccination on the severity of MenB disease presentation and outcomes., Methods: In this active, prospective, national surveillance study, we used data from the UK Health Security Agency national surveillance of meningococcal disease. We included data from follow-up of children younger than 5 years with laboratory-confirmed MenB disease who were eligible for 4CMenB vaccination with general practice 3-6 months after disease onset. All invasive MenB isolates were tested using the Meningococcal Antigen Typing System to determine whether the isolate was potentially preventable by 4CMenB. Admission to intensive care, death, and, when possible, reported sequelae in survivors were reviewed alongside vaccine status. For the epidemiological analysis, we compared laboratory-confirmed MenB disease cases before 4CMenB implementation (Sept 1, 2010, to March 31, 2015) with those after implementation (Sept 1, 2015, to March 31, 2020). For clinical follow-up and outcomes, we included all children younger than 5 years with laboratory-confirmed MenB disease between Sept 1, 2015, and March 31, 2021., Findings: Between Sept 1, 2015, and March 31, 2021, there were 371 cases of MenB disease in children younger than 5 years, including 256 (69%) in those younger than 1 year and 128 (35%) in those younger than 3 months. After the introduction of 4CMenB, the peak age of patients with MenB disease shifted from 5-6 months to 1-3 months. Overall, 108 (29%) of 371 children were too young for vaccination, unvaccinated, or developed MenB disease within 14 days of the first dose. Of 110 meningococcal strains characterised, 11 (92%) of 12 were potentially preventable by 4CMenB in unvaccinated children compared with 53 (66%) of 80 in partly vaccinated and 11 (69%) of 16 in fully vaccinated children. 78 (21%) of 371 children required intensive care, and the case fatality ratio was 5% (17 of 371), with 11 of 17 deaths occurring before 1 year of age, including seven in infants who were too young (<8 weeks) for vaccination. Of 354 survivors, 57 (16%) had 74 sequelae reported; 45 (61%) of 74 were neurological, 17 (23%) were physical, two (3%) were behavioural or psychological, and ten (14%) were other complications. Prevalence of sequelae was similar in unvaccinated (15 [15%] of 98) and vaccinated (42 [16%] 256) children, as were composite outcomes of death or sequelae, and intensive care or death or sequelae., Interpretation: Cases of MenB disease in vaccine-eligible children declined after 4CMenB implementation, but morbidity in vaccinated and unvaccinated children remained unchanged, highlighting the importance of vaccination to prevent MenB disease. The lower peak age of infants with MenB disease after 4CMenB implementation, with a higher case fatality ratio in young infants, highlights the importance of timely vaccination., Funding: UK Health Security Agency., Competing Interests: Declaration of interests SNL, RB, JL, SAC, and XB carry out contract research for vaccine manufacturers (including GlaxoSmithKline, Pfizer, and Sanofi Pasteur) on behalf of St George's University of London (SNL) and UKHSA but receive no personal remuneration. The Immunisation and Vaccine Preventable Diseases Division at UKHSA has provided vaccine manufacturers with post-marketing surveillance reports on meningococcal, Haemophilus influenzae, and pneumococcal infections, which the companies are required to submit to the UK Licensing Authority in compliance with their risk management strategy. A cost recovery charge is made for these reports. All other authors declare no competing interests., (Copyright © 2023 Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.)
- Published
- 2023
- Full Text
- View/download PDF
6. Following the Omicron wave, the majority of children in England have evidence of previous COVID infection.
- Author
-
Oeser C, Whitaker H, Borrow R, Linley E, Tonge S, Rowe C, Otter A, Warrener L, Campbell C, Ladhani S, Ramsay M, Brown KE, and Amirthalingam G
- Subjects
- Humans, Child, England epidemiology, COVID-19
- Published
- 2023
- Full Text
- View/download PDF
7. Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network.
- Author
-
Whitaker H, Tsang RSM, Button E, Andrews N, Byford R, Borrow R, Hobbs FDR, Brooks T, Howsam G, Brown K, Macartney J, Gower C, Okusi C, Hewson J, Sherlock J, Linley E, Tripathy M, Otter AD, Williams J, Tonge S, de Lusignan S, and Amirthalingam G
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, England epidemiology, Humans, Middle Aged, Primary Health Care, SARS-CoV-2, Seroepidemiologic Studies, Young Adult, COVID-19 epidemiology, General Practitioners
- Abstract
Objectives: To monitor changes in seroprevalence of SARS-CoV-2 antibodies in populations over time and between different demographic groups., Methods: A subset of practices in the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) sentinel network provided serum samples, collected when volunteer patients had routine blood tests. We tested these samples for SARS-CoV-2 antibodies using Abbott (Chicago, USA), Roche (Basel, Switzerland) and/or Euroimmun (Luebeck, Germany) assays, and linked the results to the patients' primary care computerised medical records. We report seropositivity by region and age group, and additionally examined the effects of gender, ethnicity, deprivation, rurality, shielding recommendation and smoking status., Results: We estimated seropositivity from patients aged 18-100 years old, which ranged from 4.1% (95% CI 3.1-5.3%) to 8.9% (95% CI 7.8-10.2%) across the different assays and time periods. We found higher Euroimmun seropositivity in younger age groups, people of Black and Asian ethnicity (compared to white), major conurbations, and non-smokers. We did not observe any significant effect by region, gender, deprivation, or shielding recommendation., Conclusions: Our results suggest that prior to the vaccination programme, most of the population remained unexposed to SARS-CoV-2., Competing Interests: Declaration of Competing Interest EL, ST, RB report the Public Health England Vaccine Evaluation Unit performs contract research on behalf of GSK, Sanofi and Pfizer which is outside the submitted work. Prof Lusignan reports and through his University he has had grants not directly relating to this work from AstraZeneca, GSK, Pfizer, Sanofi, Seqirus and Takeda for vaccine related research and membership of advisory boards for AstraZeneca, Sanofi and Seqirus., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
8. Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the delta wave and vaccination.
- Author
-
Oeser C, Whitaker H, Linley E, Borrow R, Tonge S, Brown CS, Gower C, Warrener L, Brown KE, Ramsay M, and Amirthalingam G
- Subjects
- Child, England epidemiology, Humans, Seroepidemiologic Studies, Vaccination, COVID-19 prevention & control, SARS-CoV-2
- Published
- 2022
- Full Text
- View/download PDF
9. Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England.
- Author
-
Ladhani SN, Campbell H, Amin-Chowdhury Z, Lucidarme J, Borrow R, and Ramsay ME
- Subjects
- Aged, Child, Preschool, England epidemiology, Humans, Infant, Vaccination, Meningococcal Infections epidemiology, Meningococcal Infections prevention & control, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B
- Abstract
Background: Timely vaccination is critical for providing early protection against meningococcal B (MenB) disease because of the high incidence in early childhood. We assessed the timeliness of vaccination in children with confirmed MenB disease after 4CMenB (a recombinant protein-based vaccine) implementation into the national infant immunisation programme in England., Methods: Public Health England (PHE) conducts surveillance of invasive meningococcal disease (IMD) in England. Children born since 01 July 2015 who developed MenB disease between 01 September 2015 and 31 August 2019 (four surveillance years) were included in the analysis., Results: There were 276 children with laboratory-confirmed MenB disease, including 36 infants who were too young for vaccination, 59 who were eligible for one 4CMenB dose, 104 for two doses and 77 for 3 doses before they developed MenB disease. Prior to developing MenB disease, there were 59 opportunities for vaccination with two 4CMenB doses in 48/104 (46.5%) eligible infants and 41 opportunities in 28/77 (36.6%) children aged ≥ 1 year who were under-immunised. A schedule with a shorter interval at 8 and 12 weeks of age, compared to the current schedule at 8 and 16 weeks, had the potential to offer an additional 4CMenB dose to 35/58 infants (58.6%) who developed MenB disease between 10 and 18 weeks of age., Conclusions: A high proportion of infants and toddlers with laboratory-confirmed MenB disease had not received their scheduled 4CMenB vaccine prior to developing MenB disease. An infant priming schedule with a shorter interval of 4 weeks has the potential to provide earlier protection against MenB disease., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
10. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study.
- Author
-
Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME, and Ladhani SN
- Subjects
- Adolescent, England epidemiology, Humans, Serogroup, Vaccines, Conjugate administration & dosage, Disease Outbreaks prevention & control, Immunization Programs, Meningococcal Infections epidemiology, Meningococcal Infections prevention & control, Meningococcal Vaccines administration & dosage, Neisseria meningitidis immunology, Neisseria meningitidis, Serogroup W-135 immunology
- Abstract
Background: In August, 2015, the UK implemented an emergency adolescent immunisation programme with the meningococcal ACWY conjugate vaccine to combat a national outbreak of meningococcal group W (MenW) disease due to a hypervirulent ST-11 complex strain, which is currently causing regional and national outbreaks worldwide. This immunisation programme specifically targeted adolescents aged 13-18 years, an age group with low disease incidence but high nasopharyngeal carriage, with the aim of interrupting transmission and providing indirect (herd) protection across the population. Here, we report the impact of the first 4 years of the programme in England., Methods: Public Health England conducts meningococcal disease surveillance in England. Laboratory-confirmed cases of invasive meningococcal disease during the academic years 2010-11 to 2014-15 (Sept 1 to Aug 31) were used to predict post-vaccination trends, based on the assumption that cases would plateau 1 year after vaccine implementation (conservative scenario) or that cases would continue to rise for 4 years after vaccine implementation (extreme scenario). Vaccine uptake evaluated in August, 2019, was 37-41% in adolescents aged 18 years immunised in primary care and 71-86% in younger teenagers routinely vaccinated in school. Vaccine effectiveness was estimated with the indirect screening method., Findings: MenW and MenY cases plateaued within 12 months and then declined, while MenC cases remained low throughout. Significant reductions were observed among adolescents aged 14-18 years for MenW (incidence rate ratio [IRR] 0·35 [95% CI 0·17-0·76]) and MenY (0·21 [0·07-0·59]) cases, with a non-significant reduction in MenC cases (0·11 [0·01-1·01]). Based on conservative and extreme scenarios, 205-1193 MenW cases were prevented through the indirect effects of the programme and 25 through direct protection. For MenY, an estimated 60-106 cases were prevented through the indirect effects of the programme and 19 through direct protection. Ignoring any residual effect from an earlier MenC-containing vaccine, the overall vaccine effectiveness against MenCWY disease combined was 94% (95% CI 80-99)., Interpretation: A meningococcal immunisation programme specifically targeting adolescent carriers succeeded in rapidly controlling a national MenW outbreak, even with moderate initial vaccine uptake., Funding: Public Health England., (Crown Copyright © 2022 Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19).
- Author
-
Willerton L, Lucidarme J, Walker A, Lekshmi A, Clark SA, Walsh L, Bai X, Lee-Jones L, and Borrow R
- Subjects
- Anti-Bacterial Agents pharmacology, Ceftriaxone pharmacology, Ceftriaxone therapeutic use, Ciprofloxacin pharmacology, Ciprofloxacin therapeutic use, England epidemiology, Humans, Meningitis, Meningococcal epidemiology, Neisseria meningitidis isolation & purification, Northern Ireland epidemiology, Penicillins pharmacology, Penicillins therapeutic use, Rifampin pharmacology, Rifampin therapeutic use, Wales epidemiology, Anti-Bacterial Agents therapeutic use, Drug Resistance, Microbial, Meningitis, Meningococcal drug therapy, Neisseria meningitidis drug effects
- Abstract
Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, can have a fatality rate as high as 10%, even with appropriate treatment. In the UK, penicillin is administered to patients in primary care whilst third generation cephalosporins, cefotaxime and ceftriaxone, are administered in secondary care. The first-choice antibiotic for chemoprophylaxis of close contacts is ciprofloxacin, followed by rifampicin. Immunocompromised individuals are often recommended antibiotic chemoprophylaxis and vaccination due to a greater risk of IMD. Resistance to antibiotics among meningococci is relatively rare, however reduced susceptibility and resistance to penicillin are increasing globally. Resistance to third generation cephalosporins is seldom reported, however reduced susceptibility to both cefotaxime and ceftriaxone has been observed. Rifampicin resistance has been reported among meningococci, mainly following prophylaxis, and ciprofloxacin resistance, whilst uncommon, has also been reported across the globe. The Public Health England Meningococcal Reference Unit receives and characterises the majority of isolates from IMD cases in England, Wales and Northern Ireland. This study assessed the distribution of antibiotic resistance to penicillin, rifampicin, ciprofloxacin and cefotaxime among IMD isolates received at the MRU from 2010/11 to 2018/19 (n = 4,122). Out of the 4,122 IMD isolates, 113 were penicillin-resistant, five were ciprofloxacin-resistant, two were rifampicin-resistant, and one was cefotaxime-resistant. Penicillin resistance was due to altered penA alleles whilst rifampicin and ciprofloxacin resistance was due to altered rpoB and gyrA alleles, respectively. Cefotaxime resistance was observed in one isolate which had an altered penA allele containing additional mutations to those harboured by the penicillin-resistant isolates. This study identified several isolates with resistance to antibiotics used for current treatment and prophylaxis of IMD and highlights the need for continued surveillance of resistance among meningococci to ensure continued effective use., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: LW, JL, AW, AL, SAC, LWa, XB and RB perform contract research on behalf of Public Health England for GlaxoSmithKline, Pfizer, and Sanofi Pasteur. LLJ has declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
12. Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England.
- Author
-
Ladhani SN, Ireland G, Baawuah F, Beckmann J, Okike IO, Ahmad S, Garstang J, Brent AJ, Brent B, Aiano F, Amin-Chowdhury Z, Kall M, Borrow R, Linley E, Zambon M, Poh J, Warrener L, Lackenby A, Ellis J, Amirthalingam G, Brown KE, and Ramsay ME
- Subjects
- Antibodies, Viral blood, England epidemiology, Humans, Prospective Studies, Schools, Seroepidemiologic Studies, Students, COVID-19 epidemiology, COVID-19 immunology, SARS-CoV-2, Seroconversion
- Abstract
Objectives: We assessed SARS-CoV-2 infection, seroprevalence and seroconversion in students and staff when secondary schools reopened in March 2021., Methods: We initiated SARS-CoV-2 surveillance in 18 secondary schools across six regions in September 2020. Participants provided nasal swabs for RT-PCR and blood samples for SARS-CoV-2 antibodies at the beginning (September 2020) and end (December 2020) of the autumn term and at the start of the spring term (March 2021)., Findings: In March 2021, 1895 participants (1100 students:795 staff) were tested; 5.6% (61/1094) students and 4.4% (35/792) staff had laboratory-confirmed SARS-CoV-2 infection from December 2020-March 2021. Nucleoprotein-antibody seroprevalence was 36.3% (370/1018) in students and 31.9% (245/769) in staff, while spike-antibody prevalence was 39.5% (402/1018) and 59.8% (459/769), respectively, similar to regional community seroprevalence. Between December 2020 and March 2021, 14.8% (97/656; 95%CI: 12.2-17.7) students and 10.0% (59/590; 95%CI: 7.7-12.7) staff seroconverted. Weekly seroconversion rates were similar from September to December 2020 (8.0/1000) and from December 2020 to March 2021 (7.9/1000; students: 9.3/1,000; staff: 6.3/1,000)., Interpretation: By March 2021, a third of secondary school students and staff had evidence of prior infection based on N-antibody seropositivity, and an additional third of staff had evidence of vaccine-induced immunity based on S-antibody seropositivity., Competing Interests: Declaration of Competing Interest MR reports that The Immunization and Countermeasures Division has provided vaccine manufacturers with post-marketing surveillance reports on pneumococcal and meningococcal infection which the companies are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. RB and EL reports other from GSK, other from Sanofi, other from Pfizer, outside the submitted work. MK reports grants from Gilead Sciences Inc, outside the submitted work. Dr. Garstang reports grants from Public Health England, during the conduct of the study. All other authors have nothing to declare., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
13. First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England.
- Author
-
Ladhani SN, Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Clark SA, Lucidarme J, Borrow R, and Ramsay ME
- Subjects
- Adolescent, Child, Child, Preschool, England epidemiology, Humans, Infant, Prospective Studies, Meningococcal Infections epidemiology, Meningococcal Infections prevention & control, Meningococcal Vaccines, Neisseria meningitidis
- Abstract
Background: 4CMenB is a protein-based meningococcal B vaccine, but the vaccine antigens may be present on non-group B meningococci. In September 2015, the UK implemented 4CMenB into the national infant immunization program, alongside an emergency adolescent meningococcal ACWY (MenACWY) program to control a national outbreak of group W (MenW) disease caused by a hypervirulent strain belonging to the ST-11 clonal complex. The adolescent program aimed to provide direct protection for adolescents and indirect protection across the population., Methods: Public Health England conducts meningococcal disease surveillance in England. MenW cases confirmed during 4 years before and 4 years after implementation of both vaccines were analyzed. Poisson models were constructed to estimate direct protection against MenW disease offered by the infant 4CMenB program along with the indirect impact of the adolescent MenACWY program in children eligible for 4CMenB but not MenACWY., Results: Model estimates showed 69% (adjusted incidence rate ratio [aIRR], .31; 95% CI, .20-.67) and 52% (aIRR, .48; 95% CI, .28-.81) fewer MenW cases than predicted among age-cohorts that were fully- and partly-eligible for 4CMenB, respectively. There were 138 MenW cases in <5-year-olds. 4CMenB directly prevented 98 (95% CI, 34-201) cases, while the MenACWY program indirectly prevented an additional 114 (conservative) to 899 (extreme) cases over 4 years. Disease severity was similar in 4CMenB-immunized and unimmunized children., Conclusions: This is the first real-world evidence of direct protection afforded by 4CMenB against MenW:cc11 disease. 4CMenB has the potential to provide some protection against all meningococcal serogroups., (© Crown copyright 2020.)
- Published
- 2021
- Full Text
- View/download PDF
14. Invasive Meningococcal Disease, 2011-2020, and Impact of the COVID-19 Pandemic, England.
- Author
-
Subbarao S, Campbell H, Ribeiro S, Clark SA, Lucidarme J, Ramsay M, Borrow R, and Ladhani S
- Subjects
- Communicable Disease Control, England epidemiology, Humans, Pandemics, SARS-CoV-2, COVID-19, Meningococcal Infections epidemiology, Meningococcal Vaccines, Neisseria meningitidis
- Abstract
Invasive meningococcal disease incidence in England declined from 1.93/100,000 persons (1,016 cases) in 2010-11 to 0.95/100,000 (530 cases) in 2018-19 and 0.74/100,000 in 2019-20 (419 cases). During national lockdown for the coronavirus disease pandemic (April-August 2020), incidence was 75% lower than during April-August 2019.
- Published
- 2021
- Full Text
- View/download PDF
15. Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England.
- Author
-
Mesher D, Thomas SL, Linley E, Edmundson C, Checchi M, Waterboer T, Bender N, Müller M, Beddows S, Borrow R, and Soldan K
- Subjects
- Adolescent, Adult, Case-Control Studies, England epidemiology, Female, Human papillomavirus 16, Human papillomavirus 18, Humans, Seroepidemiologic Studies, Vaccination, Young Adult, Papillomavirus Infections epidemiology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines, Sexual Health
- Abstract
Background: The National HPV Immunisation Programme was introduced in England in September 2008 using the HPV16/18 bivalent vaccine. We conducted serological surveillance to explore vaccination coverage levels. We also conducted a case-control study to investigate a hypothesised cross-protective effect of the HPV16/18 vaccine against genital warts., Methods: Residual serum specimens from 16 to 20 year-old women attending six specialist sexual health services (SSHS) between 2011 and 2015 in England were tested for antibodies against HPV16 and HPV18 using a virus-like particle (VLP)-based multiplex serology assay. Patients were classified as having vaccine-induced seropositivity if they were seropositive for both HPV types and either had high antibody levels for at least one HPV type, or moderately high levels for both HPV types. Differences in vaccine-induced seropositivity by patient characteristics were investigated using logistic regression. Vaccine-induced seropositivity was then compared for patients with genital warts (cases) and matched patients without (controls)., Results: Of 3,973 serum specimens collected, 3,870 (97.4%) had a valid result. The proportion of women with vaccine-induced seropositivity decreased with age (from 78.1% in 16-year-olds to 52.6% in 20-year-olds). Vaccine-induced seropositivity was lower among women born outside the UK, from more deprived areas and with a history of chlamydia diagnosis. A difference in uptake by ethnic group was also seen but this was largely confounded by differences in deprivation and country of birth. Among 537 cases and 1,515 controls, there was little evidence of a protective effect of the bivalent HPV vaccine against genital warts (adjusted odds ratio 0.93; 95% CI: 0.74-1.18)., Discussion: Vaccine-induced seropositivity in this high-risk population was in line with vaccination coverage in the general population although was lower in some at-risk sub-groups. This study does not provide evidence to support a cross-protective effect of the HPV16/18 vaccine against genital warts., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RB and EL perform contact research on behalf of Public Health England for GSK, Pfizer and Sanofi Pasteur. TW serves on advisory boards for Merck Sharp & Dohme (MSD). The Blood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV Service has provided GSK with post-marketing surveillance reports on HPV infections; a cost recovery charge is made for these reports. All other authors have no further conflict of interests., (Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
16. Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.
- Author
-
Amirthalingam G, Whitaker H, Brooks T, Brown K, Hoschler K, Linley E, Borrow R, Brown C, Watkins N, Roberts DJ, Solomon D, Gower CM, de Waroux OLP, Andrews NJ, and Ramsay ME
- Subjects
- Antibodies, Viral, Blood Donors, Communicable Disease Control, England, Humans, Immunoglobulin G, London epidemiology, Public Health, Sensitivity and Specificity, Seroepidemiologic Studies, United Kingdom, COVID-19, SARS-CoV-2
- Abstract
We describe results of testing blood donors in London, UK, for severe acute respiratory disease coronavirus 2 (SARS-CoV-2) IgG before and after lockdown measures. Anonymized samples from donors 17-69 years of age were tested using 3 assays: Euroimmun IgG, Abbott IgG, and an immunoglobulin receptor-binding domain assay developed by Public Health England. Seroprevalence increased from 3.0% prelockdown (week 13, beginning March 23, 2020) to 10.4% during lockdown (weeks 15-16) and 12.3% postlockdown (week 18) by the Abbott assay. Estimates were 2.9% prelockdown, 9.9% during lockdown, and 13.0% postlockdown by the Euroimmun assay and 3.5% prelockdown, 11.8% during lockdown, and 14.1% postlockdown by the receptor-binding domain assay. By early May 2020, nearly 1 in 7 donors had evidence of past SARS-CoV-2 infection. Combining results from the Abbott and Euroimmun assays increased seroprevalence by 1.6%, 2.3%, and 0.6% at the 3 timepoints compared with Euroimmun alone, demonstrating the value of using multiple assays.
- Published
- 2021
- Full Text
- View/download PDF
17. Seroprevalence of SARS-CoV-2 antibodies in university students: Cross-sectional study, December 2020, England.
- Author
-
Vusirikala A, Whitaker H, Jones S, Tessier E, Borrow R, Linley E, Hoschler K, Baawuah F, Ahmad S, Andrews N, Ramsay M, Ladhani SN, Brown KE, and Amirthalingam G
- Subjects
- Cross-Sectional Studies, England epidemiology, Humans, Seroepidemiologic Studies, Students, Universities, Young Adult, COVID-19, SARS-CoV-2
- Abstract
Background: In England, the reopening of universities in September 2020 coincided with a rapid increase in SARS-CoV-2 infection rates in university aged young adults. This study aimed to estimate SARS-CoV-2 antibody prevalence in students attending universities that had experienced a COVID-19 outbreak after reopening for the autumn term in September 2020., Methods: A cross-sectional serosurvey was conducted during 02-11 December 2020 in students aged ≤ 25 years across five universities in England. Blood samples for SARS-CoV-2 antibody testing were obtained using a self-sampling kit and analysed using the Abbott SARS-CoV-2 N antibody and/or an in-house receptor binding domain (RBD) assay., Findings: SARS-CoV-2 seroprevalence in 2,905 university students was 17.8% (95%CI, 16.5-19.3), ranging between 7.6%-29.7% across the five universities. Seropositivity was associated with being younger likely to represent first year undergraduates (aOR 3.2, 95% CI 2.0-4.9), living in halls of residence (aOR 2.1, 95% CI 1.7-2.7) and sharing a kitchen with an increasing number of students (shared with 4-7 individuals, aOR 1.43, 95%CI 1.12-1.82; shared with 8 or more individuals, aOR 1.53, 95% CI 1.04-2.24). Seropositivity was 49% in students living in halls of residence that reported high SARS-CoV-2 infection rates (>8%) during the autumn term., Interpretation: Despite large numbers of cases and outbreaks in universities, less than one in five students (17.8%) overall had SARS-CoV-2 antibodies at the end of the autumn term in England. In university halls of residence affected by a COVID-19 outbreak, however, nearly half the resident students became infected and developed SARS-CoV-2 antibodies., (Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
18. SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study.
- Author
-
Ladhani SN, Baawuah F, Beckmann J, Okike IO, Ahmad S, Garstang J, Brent AJ, Brent B, Walker J, Andrews N, Ireland G, Aiano F, Amin-Chowdhury Z, Letley L, Flood J, Jones SEI, Borrow R, Linley E, Zambon M, Poh J, Saliba V, Amirthalingam G, Lopez Bernal J, Brown KE, and Ramsay ME
- Subjects
- Antibodies, Viral blood, Asymptomatic Infections, COVID-19 diagnosis, Child, Child, Preschool, England epidemiology, Female, Humans, Incidence, Male, Prospective Studies, Risk Factors, SARS-CoV-2 immunology, Seroconversion, Seroepidemiologic Studies, COVID-19 epidemiology, COVID-19 transmission, Schools
- Abstract
Background: Little is known about the risk of SARS-CoV-2 infection and transmission in educational settings. Public Health England initiated a study, COVID-19 Surveillance in School KIDs (sKIDs), in primary schools when they partially reopened from June 1, 2020, after the first national lockdown in England to estimate the incidence of symptomatic and asymptomatic SARS-CoV-2 infection, seroprevalence, and seroconversion in staff and students., Methods: sKIDs, an active, prospective, surveillance study, included two groups: the weekly swabbing group and the blood sampling group. The swabbing group underwent weekly nasal swabs for at least 4 weeks after partial school reopening during the summer half-term (June to mid-July, 2020). The blood sampling group additionally underwent blood sampling for serum SARS-CoV-2 antibodies to measure previous infection at the beginning (June 1-19, 2020) and end (July 3-23, 2020) of the summer half-term, and, after full reopening in September, 2020, and at the end of the autumn term (Nov 23-Dec 18, 2020). We tested for predictors of SARS-CoV-2 antibody positivity using logistic regression. We calculated antibody seroconversion rates for participants who were seronegative in the first round and were tested in at least two rounds., Findings: During the summer half-term, 11 966 participants (6727 students, 4628 staff, and 611 with unknown staff or student status) in 131 schools had 40 501 swabs taken. Weekly SARS-CoV-2 infection rates were 4·1 (one of 24 463; 95% CI 0·1-21·8) per 100 000 students and 12·5 (two of 16 038; 1·5-45·0) per 100 000 staff. At recruitment, in 45 schools, 91 (11·2%; 95% CI 7·9-15·1) of 816 students and 209 (15·1%; 11·9-18·9) of 1381 staff members were positive for SARS-CoV-2 antibodies, similar to local community seroprevalence. Seropositivity was not associated with school attendance during lockdown (p=0·13 for students and p=0·20 for staff) or staff contact with students (p=0·37). At the end of the summer half-term, 603 (73·9%) of 816 students and 1015 (73·5%) of 1381 staff members were still participating in the surveillance, and five (four students, one staff member) seroconverted. By December, 2020, 55 (5·1%; 95% CI 3·8-6·5) of 1085 participants who were seronegative at recruitment (in June, 2020) had seroconverted, including 19 (5·6%; 3·4-8·6) of 340 students and 36 (4·8%; 3·4-6·6) of 745 staff members (p=0·60)., Interpretation: In England, SARS-CoV-2 infection rates were low in primary schools following their partial and full reopening in June and September, 2020., Funding: UK Department of Health and Social Care., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
19. Increase in penicillin-resistant invasive meningococcal serogroup W ST-11 complex isolates in England.
- Author
-
Willerton L, Lucidarme J, Walker A, Lekshmi A, Clark SA, Gray SJ, and Borrow R
- Subjects
- Australia epidemiology, England epidemiology, Humans, Penicillins pharmacology, Serogroup, Meningococcal Infections epidemiology, Neisseria meningitidis genetics
- Abstract
Introduction: Invasive meningococcal disease (IMD) caused by serogroup W meningococci belonging to the ST-11 complex (MenW:cc11) has been increasing globally since the early 2000s. Penicillin resistance among meningococci due to the production of beta-lactamase remains relatively rare. Isolates displaying resistance and reduced susceptibility to penicillin due to alterations in the penA gene (encoding Penicillin Binding Protein 2) are increasingly reported. In 2016, a penicillin-resistant clade of MenW:cc11 isolates with altered penA genes was identified in Australia. More recently, an increase in penicillin-resistant invasive MenW:cc11 isolates was observed in England. Here, we investigate the distribution of penicillin resistance among English invasive MenW:cc11 isolates., Methods: Isolates from IMD cases in England from July 2010 to August 2019 underwent whole genome sequencing and antibiotic susceptibility testing as part of routine surveillance. The PubMLST Neisseria database was used to determine the distribution of penicillin resistance among English MenW:cc11 isolates and to identify other closely related isolates., Results: Twenty-five out of 897 English invasive MenW:cc11 isolates were resistant to penicillin; identified among six distinct sublineages and a singleton. Expansion of the Australian penicillin-resistant clade included isolates from several new countries as well as 20 English isolates. A newly identified penicillin resistance-associated lineage was also identified among several countries., Conclusion: Penicillin resistance among diverse MenW:cc11 isolates is increasing. Surveillance of antibiotic resistance among meningococci is essential to ensure continued effective use., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All authors perform contract research on behalf of Public Health England for GlaxoSmithKline, Pfizer, and Sanofi Pasteur., (Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
20. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers.
- Author
-
Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, Borrow R, Linley E, Ahmad S, Stapley L, Hallis B, Amirthalingam G, Höschler K, Parker B, Horsley A, Brooks TJG, Brown KE, Ramsay ME, and Ladhani SN
- Subjects
- Adult, Antibodies, Viral, Antibody Formation, England, Health Personnel, Humans, Prospective Studies, Public Health, COVID-19, SARS-CoV-2
- Abstract
Background: Antibody waning after SARS-CoV-2 infection may result in reduction in long-term immunity following natural infection and vaccination, and is therefore a major public health issue. We undertook prospective serosurveillance in a large cohort of healthy adults from the start of the epidemic in England., Methods: Clinical and non-clinical healthcare workers were recruited across three English regions and tested monthly from March to November 2020 for SARS-CoV-2 spike (S) protein and nucleoprotein (N) antibodies using five different immunoassays. In positive individuals, antibody responses and long-term trends were modelled using mixed effects regression., Findings: In total, 2246 individuals attended 12,247 visits and 264 were seropositive in ≥ 2 assays. Most seroconversions occurred between March and April 2020. The assays showed > 85% agreement for ever-positivity, although this changed markedly over time. Antibodies were detected earlier with Abbott (N) but declined rapidly thereafter. With the EuroImmun (S) and receptor-binding domain (RBD) assays, responses increased for 4 weeks then fell until week 12-16 before stabilising. For Roche (N), responses increased until 8 weeks, stabilised, then declined, but most remained above the positive threshold. For Roche (S), responses continued to climb over the full 24 weeks, with no sero-reversions. Predicted proportions sero-reverting after 52 weeks were 100% for Abbott, 59% (95% credible interval 50-68%) Euroimmun, 41% (30-52%) RBD, 10% (8-14%) Roche (N) < 2% Roche (S)., Interpretation: Trends in SARS-CoV-2 antibodies following infection are highly dependent on the assay used. Ongoing serosurveillance using multiple assays is critical for monitoring the course and long-term progression of SARS-CoV-2 antibodies., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
21. Use of dried blood spot samples for SARS-CoV-2 antibody detection using the Roche Elecsys ® high throughput immunoassay.
- Author
-
Mulchandani R, Brown B, Brooks T, Semper A, Machin N, Linley E, Borrow R, and Wyllie D
- Subjects
- Adolescent, Adult, England, Epidemiological Monitoring, Female, Humans, Immunoassay, Limit of Detection, Male, Middle Aged, Young Adult, Antibodies, Viral blood, COVID-19 diagnosis, COVID-19 Serological Testing methods, Dried Blood Spot Testing methods, SARS-CoV-2 immunology
- Abstract
Dried blood spot samples (DBS) provide an alternative sample type to venous blood samples for antibody testing. DBS are used by NHS for diagnosing Hepatitis C and by Public Health England for large scale HIV and Hepatitis C serosurveillance; the applicability of DBS based approaches for SARS-CoV-2 antibody detection is uncertain. The study aimed to compare antibody detection in DBS eluates using the Roche Elecsys ® immunoassay with antibody detection in paired plasma samples, using the same assay. The study was in one Police and one Fire & Rescue facility in England; it comprised of 195 participants within a larger sample COVID-19 serodiagnostics study of keyworkers, EDSAB-HOME. Outcome measures were sensitivity and specificity of DBS (the index test) relative to plasma (the reference test), at an experimental cut-off; quality of DBS sample collected; estimates of relative sensitivity of DBS vs. plasma immunoassay in a larger population. 18/195 (9.2%) participants tested positive using plasma samples. DBS sample quality varied markedly by phlebotomist, and low sample volume significantly reduced immunoassay signals. Using an experimental cut-off, sensitivity and specificity of DBS were 89.0% (95% CI 67.2, 96.9%) and 100.0% (95% CI 97.9, 100%) respectively compared with using plasma. The limit of detection for DBS is about 30 times higher than for plasma. DBS use for SARS-CoV-2 serology, though feasible, is insensitive relative to immunoassays on plasma. Sample quality impacts on assay performance. Alternatives, including the collection of capillary blood samples, should be considered for screening programs., (Crown Copyright © 2021. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
22. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
- Author
-
Biolchi A, De Angelis G, Moschioni M, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, Claus H, Gorla MCO, Hong E, Lemos APS, Lucidarme J, Taha MK, Vogel U, Comanducci M, Budroni S, Giuliani MM, Rappuoli R, Pizza M, and Boucher P
- Subjects
- Antigens, Bacterial genetics, Brazil, England, France, Germany, Humans, Infant, Serogroup, Vaccination, Wales, Meningococcal Infections prevention & control, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B genetics
- Abstract
Background: The multicomponent meningococcal serogroup B vaccine (4CMenB) is currently indicated for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB). However, genes encoding the 4CMenB antigens are also variably present and expressed in strains belonging to other meningococcal serogroups. In this study, we evaluated the ability of antibodies raised by 4CMenB immunisation to induce complement-mediated bactericidal killing of non-MenB strains., Methods: A total of 227 invasive non-MenB disease isolates were collected between 1 July 2007 and 30 June 2008 from England and Wales, France, and Germany; 41 isolates were collected during 2012 from Brazil. The isolates were subjected to genotypic analyses. A subset of 147 isolates (MenC, MenW and MenY) representative of the meningococcal genetic diversity of the total sample were tested in the human complement serum bactericidal antibody assay (hSBA) using sera from infants immunised with 4CMenB., Results: Serogroup and clonal complex repertoires of non-MenB isolates were different for each country. For the European panel, MenC, MenW and MenY isolates belonged mainly to ST-11, ST-22 and ST-23 complexes, respectively. For the Brazilian panel, most MenC and MenW isolates belonged to the ST-103 and ST-11 complexes, respectively, and most MenY isolates were not assigned to clonal complexes. Of the 147 non-MenB isolates, 109 were killed in hSBA, resulting in an overall coverage of 74%., Conclusion: This is the first study in which 147 non-MenB serogroup isolates have been analysed in hSBA to evaluate the potential of a MenB vaccine to cover strains belonging to other serogroups. These data demonstrate that antibodies raised by 4CMenB are able to induce bactericidal killing of 109 non-MenB isolates, representative of non-MenB genetic and geographic diversity. These findings support previous evidence that 4CMenB immunisation can provide cross-protection against non-MenB strains in infants, which represents an added benefit of 4CMenB vaccination., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MM and MC were, AB, GDA, ST, BB, MG, SB, SoB, MMG, RR and MP are employees of the GSK groups of companies. SoB has a patent pending (WO 2015014922 A2). PB was an employee of PRA Health Sciences c/o GSK at the time of study. MKT received grants from Pfizer and the GSK group of companies and has a patent issued (630133). JL and RB have performed contract research on behalf of Public Health England for the GSK group of companies, Pfizer, and Sanofi Pasteur. APSdL reports personal fees from Pfizer and Sanofi-Pasteur. HC and UV's institution received research grants from Novartis. MCOG and EH have nothing to disclose., (Copyright © 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
23. Geographically widespread invasive meningococcal disease caused by a ciprofloxacin resistant non-groupable strain of the ST-175 clonal complex.
- Author
-
Willerton L, Lucidarme J, Campbell H, Caugant DA, Claus H, Jacobsson S, Ladhani SN, Mölling P, Neri A, Stefanelli P, Taha MK, Vogel U, and Borrow R
- Subjects
- Ciprofloxacin pharmacology, England epidemiology, Europe, Germany epidemiology, Humans, Italy, Saudi Arabia, Serogroup, Sweden, Travel, Travel-Related Illness, Meningococcal Infections epidemiology, Neisseria meningitidis genetics
- Abstract
Introduction: Invasive meningococcal disease (IMD) caused by non-serogroupable (NG) strains mainly affects immunocompromised individuals. Reduced susceptibility to penicillin in meningococci is increasing in Europe but ciprofloxacin resistance remains rare. In 2019, three travel-related meningococcal disease cases caused by a ciprofloxacin-resistant NG strain were identified in England, leading Germany to report four additional IMD cases (2016 to 2019). We describe these and newly identified cases and characterise the strain responsible., Methods: Cases were identified as part of national surveillance and by analysing available genomes using PubMLST tools., Results: Of the cases identified in England in 2019, two geographically distinct cases developed conjunctivitis after returning from Mecca (Kingdom of Saudi Arabia) and a third linked case presented with IMD. Of the four cases from Germany, three occurred in asylum seekers - two familial and a further geographically distinct case. Further IMD cases were identified in Italy (n = 2; 2017-2018), Sweden (n = 1; 2016) and England (n = 1; 2015). A single ST-175 clonal complex (cc175) strain with genosubtype P1.22-11,15-25 was responsible. Decreased susceptibility to penicillin was widespread with three ciprofloxacin resistant subclusters. Constituent isolates were potentially covered by subcapsular vaccines., Conclusion: This disease associated NG cc175 strain exhibits resistance to antibiotics commonly used to prevent IMD but is potentially covered by subcapsular (meningococcal B) vaccines., Competing Interests: Declaration of Competing Interest LW, JL, and RB perform contract research on behalf of Public Health England for GlaxoSmithKline, Pfizer, and Sanofi Pasteur. The Public Health England Immunisation and Countermeasures Division has provided vaccine manufactures with post-marketing surveillance reports, which the Marketing Authorization Holders are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. All other authors report no potential conflicts., (Copyright © 2020. Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
24. Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England.
- Author
-
de Lusignan S, Lopez Bernal J, Zambon M, Akinyemi O, Amirthalingam G, Andrews N, Borrow R, Byford R, Charlett A, Dabrera G, Ellis J, Elliot AJ, Feher M, Ferreira F, Krajenbrink E, Leach J, Linley E, Liyanage H, Okusi C, Ramsay M, Smith G, Sherlock J, Thomas N, Tripathy M, Williams J, Howsam G, Joy M, and Hobbs R
- Subjects
- Betacoronavirus, COVID-19, Disease Outbreaks, England epidemiology, Female, Humans, Male, Public Health, SARS-CoV-2, Sentinel Surveillance, Coronavirus, Coronavirus Infections epidemiology, Disease Notification methods, Medical Records Systems, Computerized, Pandemics prevention & control, Pneumonia, Viral epidemiology, Public Health Surveillance methods
- Abstract
Background: The Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) and Public Health England (PHE) have successfully worked together on the surveillance of influenza and other infectious diseases for over 50 years, including three previous pandemics. With the emergence of the international outbreak of the coronavirus infection (COVID-19), a UK national approach to containment has been established to test people suspected of exposure to COVID-19. At the same time and separately, the RCGP RSC's surveillance has been extended to monitor the temporal and geographical distribution of COVID-19 infection in the community as well as assess the effectiveness of the containment strategy., Objectives: The aims of this study are to surveil COVID-19 in both asymptomatic populations and ambulatory cases with respiratory infections, ascertain both the rate and pattern of COVID-19 spread, and assess the effectiveness of the containment policy., Methods: The RCGP RSC, a network of over 500 general practices in England, extract pseudonymized data weekly. This extended surveillance comprises of five components: (1) Recording in medical records of anyone suspected to have or who has been exposed to COVID-19. Computerized medical records suppliers have within a week of request created new codes to support this. (2) Extension of current virological surveillance and testing people with influenza-like illness or lower respiratory tract infections (LRTI)-with the caveat that people suspected to have or who have been exposed to COVID-19 should be referred to the national containment pathway and not seen in primary care. (3) Serology sample collection across all age groups. This will be an extra blood sample taken from people who are attending their general practice for a scheduled blood test. The 100 general practices currently undertaking annual influenza virology surveillance will be involved in the extended virological and serological surveillance. (4) Collecting convalescent serum samples. (5) Data curation. We have the opportunity to escalate the data extraction to twice weekly if needed. Swabs and sera will be analyzed in PHE reference laboratories., Results: General practice clinical system providers have introduced an emergency new set of clinical codes to support COVID-19 surveillance. Additionally, practices participating in current virology surveillance are now taking samples for COVID-19 surveillance from low-risk patients presenting with LRTIs. Within the first 2 weeks of setup of this surveillance, we have identified 3 cases: 1 through the new coding system, the other 2 through the extended virology sampling., Conclusions: We have rapidly converted the established national RCGP RSC influenza surveillance system into one that can test the effectiveness of the COVID-19 containment policy. The extended surveillance has already seen the use of new codes with 3 cases reported. Rapid sharing of this protocol should enable scientific critique and shared learning., International Registered Report Identifier (irrid): DERR1-10.2196/18606., (©Simon de Lusignan, Jamie Lopez Bernal, Maria Zambon, Oluwafunmi Akinyemi, Gayatri Amirthalingam, Nick Andrews, Ray Borrow, Rachel Byford, André Charlett, Gavin Dabrera, Joanna Ellis, Alex J Elliot, Michael Feher, Filipa Ferreira, Else Krajenbrink, Jonathan Leach, Ezra Linley, Harshana Liyanage, Cecilia Okusi, Mary Ramsay, Gillian Smith, Julian Sherlock, Nicholas Thomas, Manasa Tripathy, John Williams, Gary Howsam, Mark Joy, Richard Hobbs. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 02.04.2020.)
- Published
- 2020
- Full Text
- View/download PDF
25. Invasive meningococcal disease: Timing and cause of death in England, 2008-2015.
- Author
-
Beebeejaun K, Parikh SR, Campbell H, Gray S, Borrow R, Ramsay ME, and Ladhani SN
- Subjects
- Cause of Death, England epidemiology, Humans, Incidence, Infant, Serogroup, Meningitis, Meningococcal epidemiology, Meningococcal Infections epidemiology, Meningococcal Vaccines, Neisseria meningitidis
- Abstract
Background: Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia, with death often occurring rapidly after onset of the first symptoms. Later death can also occur, but may be due to other causes, such as underlying comorbidities. The study aimed to assess the timing and cause of death in patients with invasive meningococcal disease (IMD) prior to the introduction of two new meningococcal immunisation programmes in England., Methods: Public Health England (PHE) conducts IMD surveillance in England through its national meningococcal reference unit. Laboratory-confirmed IMD cases diagnosed during 2008-2015 were linked to weekly and annual electronic death registration records as well as the Patient Demographic Service (PDS) database., Results: Overall, 6734 of 6808 (99%) laboratory-confirmed IMD cases matched to PDS, including 668 fatalities. Of these, 667 linked to an annual death registration record compared to 405 reports linked to weekly death registrations. In total, 429/667 (64%) of all deaths and 428/502 (85%) of IMD-related deaths occurred within one day of diagnosis. In total, 498/667 (75%) deaths had occured by 30 days after IMD diagnosis and 98% (490/498) of these were IMD-related. Serogroup B contributed to 64% (323/502) of IMD-related deaths, followed by serogroup W (84/502, 17%) and serogroup Y (70/502, 14%). Deaths occurring after 30 days were less likely to be IMD-related, mainly amongst ≥65 year-olds, with malignancy, chronic respiratory and cardiac conditions predominating., Conclusions: Most IMD-related deaths occurred within a day of diagnosis and nearly all IMD-related deaths occurred within 30 days of diagnosis. The rapidity of death highlights the importance of prevention through vaccination., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020. Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
26. Variable clinical presentation by the main capsular groups causing invasive meningococcal disease in England.
- Author
-
Campbell H, Andrews N, Parikh S, Ribeiro S, Gray S, Lucidarme J, Ramsay ME, Borrow R, and Ladhani SN
- Subjects
- England epidemiology, Humans, Meningococcal Infections diagnosis, Meningococcal Infections epidemiology, Meningococcal Vaccines, Neisseria meningitidis, Pneumonia, Bacterial, Sepsis epidemiology
- Abstract
Background: Invasive meningococcal disease (IMD) typically presents as meningitis, septicaemia or both. Atypical clinical presentations are rare but well-described. We aimed to assess the relationship between meningococcal capsular group, age, clinical presentation, diagnosis and outcome among IMD cases diagnosed in England during 2014., Methods: Public Health England conducts enhanced national surveillance of IMD in England. Clinical data for laboratory-confirmed MenB, MenW and MenY cases in ≥5 year-olds were used to classify presenting symptoms, diagnosis and outcomes. Multivariable logistic regression was used to assess independent associations between meningococcal capsular group, clinical presentation, gender, age and death., Results: In 2014, there were 340 laboratory-confirmed IMD cases caused by MenB (n = 179), MenW (n = 95) and MenY (n = 66). Clinical presentation with meningitis alone was more prevalent among MenB cases (28%) and among 15-24 year-olds (20%), whilst bacteraemic pneumonia was most prevalent among MenY cases (26%) and among ≥65 year-olds (24%). Gastrointestinal symptoms were recorded preceding or during presentation in 15% (40/269) cases with available information, including 5% (7/140) MenB, 17% (8/47) MenY and 30% (25/82) MenW cases. Upper respiratory tract symptoms were reported in 16% (22/141) MenB, 23% (11/47) MenY and 31% (26/84) MenW cases. Increasing age was also independently associated with bacteraemic meningococcal pneumonia, with no cases among 5-14 year-olds compared to 24% in ≥65 year-olds. Case fatality rates increased with age but no significant associations with death were identified., Conclusions: Healthcare professionals should be aware of the atypical clinical presentations associated with the less prevalent meningococcal capsular groups in different age-groups., Competing Interests: Declaration of Competing Interest HC, NA, SP, SR and MER have no personal competing interests. PHE National Infection Service, Immunisation and Countermeasures Division has provided vaccine manufactures with post-marketing surveillance reports which the Marketing Authorisation Holders are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. SL performs contract work on behalf of St George’s university of London for GlaxoSmithKline, Pfizer, and Sanofi Pasteur. RB, JL and SJG perform contract research on behalf of Public Health England for GlaxoSmithKline, Pfizer, and Sanofi Pasteur. None of these authors receive personal remuneration., (Copyright © 2019. Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
27. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England.
- Author
-
Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, and Ramsay ME
- Subjects
- Child, Preschool, Confidence Intervals, England epidemiology, Humans, Immunization Schedule, Immunization, Secondary, Incidence, Infant, Infant, Newborn, Meningococcal Infections epidemiology, State Medicine, Treatment Outcome, United Kingdom, Immunization Programs, Meningococcal Infections prevention & control, Meningococcal Vaccines immunology, Neisseria meningitidis, Serogroup B
- Abstract
Background: In September 2015, the United Kingdom introduced the multicomponent meningococcal group B vaccine (4CMenB, Bexsero) into its publicly funded national immunization program at a reduced two-dose priming schedule for infants, with a 12-month booster., Methods: Using data from enhanced national surveillance of invasive meningococcal disease in England, we evaluated the effect of vaccination on the incidence of meningococcal group B disease during the first 3 years of the program. The effect of vaccination was assessed by comparing the observed incidence of disease with the expected incidence based on the incidence during the 4-year prevaccination period in equivalent cohorts and with the use of disease trends in cohorts of children younger than 5 years of age who were not eligible to receive the vaccine. Vaccine effectiveness was estimated with the use of the indirect screening method., Results: 4CMenB uptake in England remained consistently high; data from the first 3 months of 2018 showed that 92.5% of children had completed the primary immunizations by their first birthday and 87.9% had received all three doses by 2 years. From September 2015 through August 2018, the incidence of meningococcal group B disease in England (average annual birth cohort, approximately 650,000 infants) was significantly lower in vaccine-eligible cohorts than the expected incidence (63 observed cases as compared with 253 expected cases; incidence rate ratio, 0.25; 95% confidence interval [CI], 0.19 to 0.36), with a 75% reduction in age groups that were fully eligible for vaccination. The adjusted vaccine effectiveness against meningococcal group B disease was 52.7% (95% CI, -33.5 to 83.2) with a two-dose priming schedule for infants and 59.1% (95% CI, -31.1 to 87.2) with a two-dose priming schedule plus a booster at 1 year). Over the 3-year period, there were 169 cases of meningococcal group B disease in the vaccine-eligible cohorts, and an estimated 277 cases (95% CI, 236 to 323) were prevented., Conclusions: The 4CMenB program was associated with continued positive effect against meningococcal group B disease in children in England, and protection after three doses of the vaccine was sustained for at least 2 years. (Funded by Public Health England.)., (Copyright © 2020 Massachusetts Medical Society.)
- Published
- 2020
- Full Text
- View/download PDF
28. Effect of Pneumococcal Conjugate Vaccines on Pneumococcal Meningitis, England and Wales, July 1, 2000-June 30, 2016.
- Author
-
Oligbu G, Collins S, Djennad A, Sheppard CL, Fry NK, Andrews NJ, Borrow R, Ramsay ME, and Ladhani SN
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, England epidemiology, Female, Heptavalent Pneumococcal Conjugate Vaccine administration & dosage, Humans, Incidence, Infant, Infant, Newborn, Male, Mass Vaccination, Meningitis, Pneumococcal mortality, Meningitis, Pneumococcal prevention & control, Middle Aged, Vaccines, Conjugate, Wales epidemiology, Young Adult, Meningitis, Pneumococcal epidemiology, Pneumococcal Vaccines administration & dosage, Streptococcus pneumoniae immunology
- Abstract
We describe the effects of the 7-valent (PCV7) and 13-valent (PCV13) pneumococcal conjugate vaccines on pneumococcal meningitis in England and Wales during July 1, 2000-June 30, 2016. Overall, 84,473 laboratory-confirmed invasive pneumococcal disease cases, including 4,160 (4.9%) cases with meningitis, occurred. PCV7 implementation in 2006 did not lower overall pneumococcal meningitis incidence because of replacement with non-PCV7-type meningitis incidence. Replacement with PCV13 in 2010, however, led to a 48% reduction in pneumococcal meningitis incidence by 2015-16. The overall case-fatality rate was 17.5%: 10.7% among patients <5 years of age, 17.3% among patients 5-64 years of age, and 31.9% among patients >65 years of age. Serotype 8 was associated with increased odds of death (adjusted odds ratio 2.9, 95% CI 1.8-4.7). In England and Wales, an effect on pneumococcal meningitis was observed only after PCV13 implementation. Further studies are needed to assess pneumococcal meningitis caused by the replacing serotypes.
- Published
- 2019
- Full Text
- View/download PDF
29. Outbreak strain characterisation and pharyngeal carriage detection following a protracted group B meningococcal outbreak in adolescents in South-West England.
- Author
-
Clark SA, Lucidarme J, Angel G, Lekshmi A, Morales-Aza B, Willerton L, Campbell H, Gray SJ, Ladhani SN, Wade M, Ramsay M, Yates J, Finn A, and Borrow R
- Subjects
- Adolescent, Antigens, Bacterial genetics, Bacterial Proteins genetics, Bacteriological Techniques, Disease Outbreaks, England, Humans, Meningococcal Vaccines immunology, Neisseria meningitidis, Serogroup B genetics, Neisseria meningitidis, Serogroup B isolation & purification, Phylogeny, Porins genetics, Whole Genome Sequencing methods, Carrier State epidemiology, Meningococcal Infections epidemiology, Meningococcal Vaccines administration & dosage, Neisseria meningitidis, Serogroup B classification, Pharynx microbiology
- Abstract
Between April 2016 and September 2017, four cases of group B meningococcal disease were reported among sixth-form college students in Bristol, UK. Culture and non-culture whole genome sequencing was utilised and demonstrated that the four genomes of the responsible ST-41 strains clustered closely on a sub-lineage of ST-41/44 clonal complex. The outbreak resulted in two fatalities. A distinct social group associated with one of the cases was selected for vaccination with 4CMenB and pharyngeal swabbing. In vitro culturing, multiple real-time PCR assays (sodC, ctrA and siaD
B ) and a PorA PCR-sequencing assay were used to detect meningococcal colonisation and a carriage rate of 32.6% was observed. Furthermore, a high proportion of the pharyngeal swabs (78.3%) yielded a Factor H-Binding Protein (fHbp) nucleotide allele suggesting that the antigenic gene is prevalent among non-meningococcal flora, most likely Neisseria commensals. This may have implications for fHbp as a vaccine antigen should it be shown to influence bacterial colonisation.- Published
- 2019
- Full Text
- View/download PDF
30. Lower risk of invasive meningococcal disease during pregnancy: national prospective surveillance in England, 2011-2014.
- Author
-
Parikh SR, Borrow R, Ramsay ME, and Ladhani SN
- Subjects
- Adolescent, Adult, England epidemiology, Female, Humans, Incidence, Pregnancy, Prospective Studies, Risk Factors, Serogroup, Young Adult, Meningococcal Infections epidemiology, Population Surveillance, Pregnancy Complications, Infectious epidemiology
- Abstract
Objective: To describe cases of invasive meningococcal disease (IMD) in women of childbearing age and to estimate the disease incidence and relative risk of IMD in pregnant compared with non-pregnant women., Design: Prospective enhanced national surveillance for IMD., Setting: England., Population: Women of reproductive age (15-44 years) with laboratory-confirmed IMD., Methods: Public Health England conducts enhanced national surveillance for IMD in England. Laboratory-confirmed cases are followed up with postal questionnaires to general practitioners. All cases confirmed in women of reproductive age from 1 January 2011 to 31 December 2014 were included., Main Outcome Measures: Annual IMD incidence and relative risk of IMD in pregnant compared with non-pregnant women of reproductive age., Results: During the 4-year surveillance period, there were 1502 cases of IMD in females across England; of these, 310 (20.6%) cases were in women of reproductive age, including four women who were pregnant at the time of IMD confirmation (1.3%). Serogroup distribution of IMD cases in women of childbearing age was similar to the overall distribution. The four cases in otherwise healthy pregnant women were confirmed across all trimesters and all survived; one case in the first trimester had a septic miscarriage. The incidence of IMD was lower in pregnant than in non-pregnant women (0.16 compared with 0.76 per 100 000 pregnant and non-pregnant years, respectively), giving a lower risk of IMD in pregnant women (incidence rate ratio, IRR, 0.21; 95% confidence interval, 0.06-0.54)., Conclusions: Pregnant women are nearly five times less likely to develop IMD compared with non-pregnant women, but the infection can be severe., Tweetable Abstract: The risk of meningococcal disease is lower in pregnant women compared with non-pregnant women; the infection can occur across all trimesters and can be severe., (© 2019 Royal College of Obstetricians and Gynaecologists.)
- Published
- 2019
- Full Text
- View/download PDF
31. Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017).
- Author
-
Ladhani SN, Campbell H, Lucidarme J, Gray S, Parikh S, Willerton L, Clark SA, Lekshmi A, Walker A, Patel S, Bai X, Ramsay M, and Borrow R
- Subjects
- Adolescent, Adult, Antibodies, Monoclonal, Humanized adverse effects, Child, Child, Preschool, England epidemiology, Genotype, Humans, Immunologic Deficiency Syndromes etiology, Meningococcal Infections epidemiology, National Health Programs statistics & numerical data, Polysaccharides, Bacterial genetics, Retrospective Studies, Young Adult, Complement System Proteins deficiency, Immunologic Deficiency Syndromes complications, Meningococcal Infections complications, Meningococcal Infections microbiology, Neisseria meningitidis genetics
- Abstract
Background: To describe patients with inherited and acquired complement deficiency who developed invasive meningococcal disease (IMD) in England over the last decade., Methods: Public Health England conducts enhanced surveillance of IMD in England. We retrospectively identified patients with complement deficiency who developed IMD in England during 2008-2017 and retrieved information on their clinical presentation, vaccination status, medication history, recurrence of infection and outcomes, as well as characteristics of the infecting meningococcal strain., Results: A total of 16 patients with 20 IMD episodes were identified, including four with two episodes. Six patients had inherited complement deficiencies, two had immune-mediated conditions associated with complement deficiency (glomerulonephritis and vasculitis), and eight others were on Eculizumab therapy, five for paroxysmal nocturnal haemoglobinuria and three for atypical haemolytic uraemic syndrome. Cultures were available for 7 of 11 episodes among those with inherited complement deficiencies/immune-mediated conditions and the predominant capsular group was Y (7/11), followed by B (3/11) and non-groupable (1/11) strains. Among patients receiving Eculizumab therapy, 3 of the 9 episodes were due to group B (3/9), three others were NG but genotypically group B, and one case each of groups E, W and Y., Conclusions: In England, complement deficiency is rare among IMD cases and includes inherited disorders of the late complement pathway, immune-mediated disorders associated with low complement levels and patients on Eculizumab therapy. IMD due to capsular group Y predominates in patient with inherited complement deficiency, whilst those on Eculizumab therapy develop IMD due to more diverse capsular groups including non-encapsulated strains.
- Published
- 2019
- Full Text
- View/download PDF
32. Suspected cluster of Neisseria meningitidis W invasive disease in an elderly care home: do new laboratory methods aid public health action? United Kingdom, 2015.
- Author
-
Lawler J, Lucidarme J, Parikh S, Smith L, Campbell H, Borrow R, Gray S, Foster K, and Ladhani S
- Subjects
- Aged, Aged, 80 and over, Carrier State microbiology, Disease Outbreaks, England epidemiology, Homes for the Aged, Humans, Incidence, Male, Meningococcal Infections epidemiology, Meningococcal Infections microbiology, Meningococcal Infections transmission, Meningococcal Vaccines immunology, Neisseria meningitidis classification, Neisseria meningitidis genetics, Neisseria meningitidis, Serogroup W-135 genetics, Nursing Homes, Phenotype, Whole Genome Sequencing methods, Carrier State epidemiology, Meningococcal Infections diagnosis, Meningococcal Vaccines administration & dosage, Neisseria meningitidis isolation & purification, Neisseria meningitidis, Serogroup W-135 isolation & purification, Serogroup
- Abstract
In 2015, a suspected cluster of two invasive meningococcal disease (IMD) cases of serogroup W Neisseria meningitidis (MenW) occurred in elderly care home residents in England over 7 months; case investigations followed United Kingdom guidance. An incident control team reviewed epidemiological information. Phenotyping of case specimens informed public health action, including vaccination and throat swabs to assess carriage. Whole genome sequencing (WGS) was conducted on case and carrier isolates. Conventional phenotyping did not exclude a microbiological link between cases (case 1 W:2a:P1.5,2 and case 2 W:2a:NT). After the second case, 33/40 residents and 13/32 staff were vaccinated and 19/40 residents and 13/32 staff submitted throat swabs. Two MenW carriers and two MenC carriers were detected. WGS showed that MenW case and carrier isolates were closely related and possibly constituted a locally circulating strain. Meningococcal carriage, transmission dynamics and influence of care settings on IMD in older adults are poorly understood. WGS analyses performed following public health action helped to confirm the close relatedness of the case and circulating isolates despite phenotypic differences and supported actions taken. WGS was not sufficiently timely to guide public health practice.
- Published
- 2019
- Full Text
- View/download PDF
33. Serological surveillance of influenza in an English sentinel network: pilot study protocol.
- Author
-
de Lusignan S, Borrow R, Tripathy M, Linley E, Zambon M, Hoschler K, Ferreira F, Andrews N, Yonova I, Hriskova M, Rafi I, and Pebody R
- Subjects
- Adult, Aged, England epidemiology, Female, Humans, Influenza Vaccines, Influenza, Human virology, Male, Middle Aged, Pilot Projects, Seroepidemiologic Studies, Young Adult, Influenza, Human blood, Influenza, Human epidemiology, Sentinel Surveillance
- Abstract
Background: Rapidly undertaken age-stratified serology studies can produce valuable data about a new emerging infection including background population immunity and seroincidence during an influenza pandemic. Traditionally seroepidemiology studies have used surplus laboratory sera with little or no clinical information or have been expensive detailed population based studies. We propose collecting population based sera from the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), a sentinel network with extensive clinical data., Aim: To pilot a mechanism to undertake population based surveys that collect serological specimens and associated patient data to measure seropositivity and seroincidence due to seasonal influenza, and create a population based serology bank. METHODS AND ANALYSIS: Setting and Participants: We will recruit 6 RCGP RSC practices already taking nasopharyngeal virology swabs. Patients who attend a scheduled blood test will be consented to donate additional blood samples. Approximately 100-150 blood samples will be collected from each of the following age bands - 18- 29, 30- 39, 40- 49, 50- 59, 60- 69 and 70+ years., Methods: We will send the samples to the Public Health England (PHE) Seroepidemiology Unit for processing and storage. These samples will be tested for influenza antibodies, using haemagglutination inhibition assays. Serology results will be pseudonymised, sent to the RCGP RSC and combined using existing processes at the RCGP RSC secure hub. The influenza seroprevalence results from the RCGP cohort will be compared against those from the annual PHE influenza residual serosurvey., Ethics and Dissemination: Ethical approval was granted by the Proportionate Review Sub- Committee of the London - Camden & Kings Cross on 6 February 2018. This study received approval from Health Research Authority on 7 February 2018. On completion the results will be made available via peer-reviewed journals., Competing Interests: Competing interests: Simon de Lusignan has received grant funding through University of Surrey from GSK to report vaccine adverse events and attended advisory boards for Sanofi and Seqirus., (© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
34. Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16.
- Author
-
Findlow H, Campbell H, Lucidarme J, Andrews N, Linley E, Ladhani S, and Borrow R
- Subjects
- Adolescent, Adult, Child, Child, Preschool, England epidemiology, Female, Humans, Immunization Programs, Incidence, Infant, Male, Meningitis, Meningococcal prevention & control, Meningococcal Infections prevention & control, Meningococcal Vaccines administration & dosage, Neisseria meningitidis, Serogroup C isolation & purification, Seroepidemiologic Studies, Vaccination, Young Adult, Meningitis, Meningococcal epidemiology, Meningococcal Infections epidemiology, Meningococcal Vaccines immunology, Neisseria meningitidis, Serogroup C immunology
- Abstract
BackgroundIn 1999, the United Kingdom (UK) was the first country to introduce meningococcal group C (MenC) conjugate vaccination. This vaccination programme has evolved with further understanding, new vaccines and changing disease epidemiology.AimTo characterise MenC disease and population protection against MenC disease in England.MethodsBetween 1998/99-2015/16, surveillance data from England for laboratory-confirmed MenC cases were collated; using the screening method, we updated vaccine effectiveness (VE) estimates. Typing data and genomes were obtained from the Meningitis Research Foundation Meningococcus Genome Library and PubMLST Neisseria database. Phylogenetic network analysis of MenC cc11 isolates was undertaken. We compared bactericidal antibody assay results using anonymised sera from 2014 to similar data from 1996-1999, 2000-2004 and 2009.ResultsMenC cases fell from 883 in 1998/99 (1.81/100,000 population) to 42 cases (0.08/100,000 population) in 2015/16. Lower VE over time since vaccination was observed after infant immunisation (p = 0.009) and a single dose at 1-4 years (p = 0.03). After vaccination at 5-18 years, high VE was sustained for ≥ 8 years; 95.0% (95% CI: 76.0- 99.5%). Only 25% (75/299) children aged 1-14 years were seroprotected against MenC disease in 2014. Recent case isolates mostly represented two cc11 strains.ConclusionHigh quality surveillance has furthered understanding of MenC vaccines and improved schedules, maximising population benefit. The UK programme provides high direct and indirect protection despite low levels of seroprotection in some age groups. High-resolution characterisation supports ongoing surveillance of distinct MenC cc11 lineages.
- Published
- 2019
- Full Text
- View/download PDF
35. Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010-2016.
- Author
-
Makwana A, Sheppard C, Borrow R, Fry N, Andrews NJ, and Ladhani SN
- Subjects
- Child, Preschool, England epidemiology, Epidemiological Monitoring, Female, Humans, Infant, Male, Meningitis epidemiology, Meningitis microbiology, Pneumococcal Infections complications, Prevalence, Public Health, Respiratory Tract Infections microbiology, Serogroup, Streptococcus pneumoniae, Wales epidemiology, Comorbidity, Pneumococcal Infections epidemiology, Pneumococcal Vaccines therapeutic use, Respiratory Tract Infections epidemiology
- Abstract
Background: In England and Wales, replacement of childhood 7-valent pneumococcal conjugate vaccine (PCV7) with a 13-valent vaccine (PCV13) in 2010 was associated with a significant reduction in PCV13-serotype invasive pneumococcal disease (IPD), with a small increase in IPD due to non-vaccine serotypes. Here, we describe the clinical presentation, comorbidity prevalence, serotype distribution and outcomes of childhood IPD during the first 6 years after PCV13 introduction., Methods: Public Health England conducts enhanced IPD surveillance in England and Wales, with detailed information requested from general practitioners for all cases in children <5 years of age. Invasive isolates are routinely serotyped at the Public Health England reference laboratory., Results: From April 2010 to March 2016, 1280 IPD episodes were confirmed in 1255 children 3-59 months of age; 84.3% (1059/1255) isolates were serotyped. Clinical presentation with meningitis was most prevalent in 3- to 11-month olds (45.8%, 209/456) and lower respiratory tract infection in 24- to 59-month olds (46.7%, 133/285). Overall, 259 (20.6%) children had 292 comorbidities, particularly immunosuppression (31.6%, 92/292). Twenty-one children (1.8%) had recurrent IPD. The case fatality rate was 5.1% (64/1255; 95% confidence interval [CI]: 3.9%-6.5%) and independently associated with meningitis (aOR 3.53; 95% CI: 1.62-7.70) and presence of comorbidity (aOR, 2.41; 95% CI: 1.25-4.64). In 2015/2016, PCV13 serotypes were responsible for 10.8% (25/232) of serotyped cases; the most prevalent non-PCV13 serotypes were 12F (18%), 10A (12%), 23B (10%), 33F (10%), 15B/C (10%) and 8 (8%)., Conclusions: Most childhood IPD cases are now due to non-PCV13 serotypes. A higher proportion of children with IPD have underlying comorbidity, but, reassuringly, the risk of recurrent IPD or death remains low.
- Published
- 2018
- Full Text
- View/download PDF
36. Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010-2015.
- Author
-
Parikh SR, Campbell H, Gray SJ, Beebeejaun K, Ribeiro S, Borrow R, Ramsay ME, and Ladhani SN
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, England epidemiology, Female, Follow-Up Studies, Humans, Incidence, Infant, Infant, Newborn, Male, Middle Aged, Neisseria meningitidis classification, Neisseria meningitidis isolation & purification, Risk Factors, Surveys and Questionnaires, Treatment Outcome, Young Adult, Critical Care statistics & numerical data, Meningococcal Infections epidemiology, Meningococcal Infections pathology
- Abstract
The epidemiology of invasive meningococcal disease (IMD) is constantly changing as new strains are introduced into a population and older strains are removed through vaccination, population immunity or natural trends. Consequently, the clinical disease associated with circulating strains may also change over time. In England, IMD incidence has declined from 1.8/100,000 in 2010/2011 to 1.1/100,000 in 2013/2014, with a small increase in 2014/2015 to 1.3/100,000. Between 01 January 2011 and 30 June 2015, MenB was responsible for 73.0% (n = 2489) of 3411 laboratory-confirmed IMD cases, followed by MenW (n = 371, 10.9%), MenY (n = 373, 10.9%) and MenC (n = 129, 3.8%); other capsular groups were rare (n = 49, 1.4%). Detailed questionnaires were completed for all 3411 laboratory-confirmed cases. Clinical presentation varied by capsular group and age. Atypical presentations were uncommon (244/3411; 7.2%), increasing from 1.2% (41/3411) in children to 3.5% (120/3411) in older adults. Known IMD risk factors were rare (18/3411; 0.5%) and included complement deficiency (n = 11), asplenia (n = 6) or both (n = 1). Nearly a third of cases required intensive care (1069/3411; 31.3%), with rates highest in adults. The 28-day CFR was 6.9% (n = 237), with the lowest rates in 0-14 year-olds (85/1885, 4.5%) and highest among 85+ year-olds (30/94, 31.9%). These observations provide a useful baseline for the current burden of IMD in a European country with enhanced national surveillance., (Copyright © 2018. Published by Elsevier Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
37. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
- Author
-
Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, and Ramsay ME
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, England epidemiology, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Middle Aged, Prospective Studies, Wales epidemiology, Young Adult, Heptavalent Pneumococcal Conjugate Vaccine immunology, Pneumococcal Infections epidemiology, Pneumococcal Infections microbiology, Pneumococcal Vaccines immunology, Serogroup, Streptococcus pneumoniae classification, Streptococcus pneumoniae isolation & purification
- Abstract
Background: Pneumococcal conjugate vaccines (PCVs) have substantially reduced the incidence of invasive pneumococcal disease caused by vaccine serotypes; however, replacement disease with non-PCV serotypes remains a concern. We describe the population effect of the seven-valent and 13-valent PCVs (PCV7 and PCV13) on invasive pneumococcal disease in England and Wales., Methods: Using national invasive pneumococcal disease surveillance data for 2016/17, we compared incidence rate ratios (IRRs) against pre-PCV13 (2008/09-2009/10) and pre-PCV7 (2000/01-2005/06) baselines. We also estimated the number of invasive pneumococcal disease cases prevented since the introduction of PCVs., Findings: In 2016/17, overall invasive pneumococcal disease incidence (9·87 cases per 100 000; 5450 cases) across all age groups was 37% lower (IRR 0·63, 95% CI 0·60-0·65) than pre-PCV7 incidence (14·79 per 100 000; 8167 cases) and 7% lower (0·93; 0·89-0·97) than pre-PCV13 incidence (10·13 per 100 000; 5595 cases). By 2016/17, PCV7-type invasive pneumococcal disease incidence across all age groups had decreased by 97% (0·24 per 100 000; 0·03, 0·02-0·04) compared with the pre-PCV7 period, whereas additional PCV13-type invasive pneumococcal disease decreased by 64% (1·66 per 100 000; 0·36, 0·32-0·40) since the introduction of PCV13. Invasive pneumococcal disease incidence due to non-PCV13 serotypes doubled (7·97 per 100 000; 1·97, 1·86-2·09) since the introduction of PCV7, and accelerated since 2013/14-especially serotypes 8, 12F, and 9N, which were responsible for more than 40% of invasive pneumococcal disease cases by 2016/17. Invasive pneumococcal disease incidence in children younger than 5 years remained stable since 2013/14, with nearly all replacement disease occurring in adults. We estimated 38 366 invasive pneumococcal disease cases were prevented in the 11 years since the introduction of PCV7., Interpretation: Both PCV7 and PCV13 have had a major effect in reducing the burden of invasive pneumococcal disease in England and Wales; however, rapid increases in some non-PCV13 serotypes are compromising the benefits of the programme., Funding: Public Health England., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
38. Targeted DNA enrichment and whole genome sequencing of Neisseria meningitidis directly from clinical specimens.
- Author
-
Clark SA, Doyle R, Lucidarme J, Borrow R, and Breuer J
- Subjects
- Base Sequence, DNA, Bacterial genetics, England, Humans, Meningococcal Infections microbiology, Neisseria meningitidis isolation & purification, Sequence Analysis, DNA methods, Wales, Whole Genome Sequencing methods, Genome, Bacterial genetics, Neisseria meningitidis genetics, Nucleic Acid Amplification Techniques methods
- Abstract
In England and Wales, approximately one half of all laboratory-confirmed meningococcal disease cases fail to yield a viable invasive isolate, primarily due to the use of antibiotics. Characterisation of non-culture meningococci has been restricted to the detection or sequencing of specific gene targets within clinical specimens. In this study we investigated the ability of the Agilent SureSelectXT kit to facilitate DNA enrichment and genome sequencing of meningococcal DNA within a small panel of blood and CSF specimens. A target-specific RNA oligonucleotide bait library was used to capture and enrich the bacterial DNA prior to next generation sequencing. A positive correlation between meningococcal DNA amount and genome coverage was observed with eight of the ten specimens producing genomes of acceptable quality. All commonly-used typing information derived from each acceptable non-culture genome matched those of an isolate from the same patient and the paired genomes showed a high level of congruence across indexed loci. We estimate that this technique could be used to perform whole genome sequencing on up to ∼45% of the positive specimens received by the Public Health England's Meningococcal Reference Unit. Further optimisation of the extraction and/or enrichment processes may, however, increase the proportion of non-culture cases from which quality genomes can be obtained., (Crown Copyright © 2017. Published by Elsevier GmbH. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
39. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study.
- Author
-
Knol MJ, Hahné SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, Borrow R, Ladhani SN, Ramsay ME, and van der Ende A
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Cohort Studies, England epidemiology, Female, Humans, Incidence, Infant, Male, Middle Aged, Neisseria meningitidis isolation & purification, Neisseria meningitidis, Serogroup C isolation & purification, Netherlands epidemiology, Serogroup, Young Adult, Disease Outbreaks, Meningococcal Infections epidemiology, Meningococcal Infections microbiology, Neisseria meningitidis genetics
- Abstract
Background: Since 2009, the incidence of meningococcal serogroup W disease has increased rapidly in the UK because of a single strain (the so-called original UK strain) belonging to the hypervirulent sequence type-11 clonal complex (cc11), with a variant outbreak strain (the so-called 2013 strain) emerging in 2013. Subsequently, the Netherlands has had an increase in the incidence of meningococcal serogroup W disease. We assessed the temporal and phylogenetic associations between the serogroup W outbreaks in the Netherlands and England, and the historical serogroup C outbreaks in both countries., Methods: For this observational cohort study, we used national surveillance data for meningococcal serogroup W and serogroup C disease in the Netherlands and England for the epidemiological years (July to June) 1992-93 to 2015-16. We also did whole genome sequencing and core genome multilocus sequence typing (1546 loci) on serogroup W disease isolates from both countries for surveillance years 2008-09 to 2015-16. We used Poisson regression to compare the annual relative increase in the incidence of serogroup W and serogroup C between both countries., Findings: In the Netherlands, the incidence of meningococcal serogroup W disease increased substantially in 2015-16 compared with 2014-15, with an incidence rate ratio of 5·2 (95% CI 2·0-13·5) and 11% case fatality. In England, the incidence increased substantially in 2012-13 compared with 2011-12, with an incidence rate ratio of 1·8 (1·2-2·8). The relative increase in the Netherlands from 2014-15 to 2015-16 was 418% (95% CI 99-1248), which was significantly higher than the annual relative increase of 79% (61-99) per year in England from 2011-12 to 2014-15 (p=0·03). Cases due to meningococcal serogroup W cc11 (MenW:cc11) emerged in 2012-13 in the Netherlands. Of 29 MenW:cc11 cases found up to 2015-16, 26 (90%) were caused by the 2013 strain. For both the current serogroup W outbreak and the historical serogroup C outbreak, the increase in incidence started several years later in the Netherlands than in England, the rate of increase was higher in the Netherlands, and age distributions were similar in both countries., Interpretation: Given the historical similarities of meningococcal serogroup W with meningococcal serogroup C emergence, the rapid expansion of the MenW:cc11 2013 strain in the Netherlands, its high case fatality, and the availability of a safe and effective vaccine, urgent consideration is needed for public health interventions in the Netherlands and other affected countries to prevent further serogroup W cases and deaths., Funding: National Institute for Public Health and the Environment (Netherlands), Academic Medical Center (Netherlands), and Public Health England., (Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
40. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
- Author
-
Oligbu G, Collins S, Andrews N, Sheppard CL, Fry NK, Slack MPE, Borrow R, and Ladhani SN
- Subjects
- Child, Preschool, England, Female, Heptavalent Pneumococcal Conjugate Vaccine immunology, Humans, Immunization methods, Incidence, Infant, Male, Respiratory Tract Infections immunology, Respiratory Tract Infections microbiology, Risk Factors, Serogroup, Serotyping methods, Streptococcus pneumoniae immunology, Vaccination methods, Wales, Pneumococcal Infections immunology, Pneumococcal Vaccines immunology, Vaccines, Conjugate immunology
- Abstract
Background: The 7-valent and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) are highly effective in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes. Vaccine failure (vaccine-type IPD after age-appropriate immunization) is rare. Little is known about the risk, clinical characteristics, or outcomes of PCV13 compared to PCV7 vaccine failure., Methods: Public Health England conducts IPD surveillance and provides a national reference service for serotyping pneumococcal isolates in England and Wales. We compared the epidemiology, rates, risk factors, serotype distribution, clinical characteristics, and outcomes of IPD in children with PCV13 and PCV7 vaccine failure., Results: A total of 163 episodes of PCV failure were confirmed in 161 children over 8 years (4 September 2006 to 3 September 2014) in 10 birth cohorts. After 3 vaccine doses, PCV7 and PCV13 failure rates were 0.19/100000 (95% confidence interval [CI], .10-.33 [57 cases]) and 0.66/100000 (95% CI, .44-.95 [104 cases]) vaccinated person-years, respectively. Children with PCV13 failure were more likely to be healthy (87/105 [82.9%] vs 37/56 [66.1%]; P = .02), present with bacteremic lower respiratory tract infection (LRTI) (61/105 [58.1%] vs 11/56 [19.6%]; P < .001), and develop empyema (41/61 [67.2%] vs 1/11 [9.1%]; P < .001) compared to PCV7 failures. Serotypes 3 (n = 38 [36.2%]) and 19A (n = 30 [28.6%]) were responsible for most PCV13 failures. Six children died (4% [95% CI, 1%-8%]), including 5 with comorbidities., Conclusions: PCV failure is rare and, compared to PCV7 serotypes, the additional PCV13 serotypes are more likely to cause bacteremic LRTI and empyema in healthy vaccinated children., (© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
41. Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015-2016.
- Author
-
Campbell H, Edelstein M, Andrews N, Borrow R, Ramsay M, and Ladhani S
- Subjects
- Adolescent, Age Factors, England epidemiology, Female, History, 21st Century, Humans, Male, Meningococcal Infections history, Outcome Assessment, Health Care, Immunization Programs, Meningococcal Infections prevention & control, Meningococcal Vaccines immunology, Neisseria meningitidis immunology, Vaccination
- Abstract
During the first 12 months of an emergency meningococcal ACWY vaccination program for teenagers in England, coverage among persons who left school in 2015, the first cohort to be vaccinated, was 36.6%. There were 69% fewer group W meningococcal cases than predicted by trend analysis and no cases in vaccinated teenagers.
- Published
- 2017
- Full Text
- View/download PDF
42. Clinical diagnoses and outcomes of 4619 hospitalised cases of laboratory-confirmed invasive meningococcal disease in England: Linkage analysis of multiple national databases.
- Author
-
Edge C, Waight P, Ribeiro S, Borrow R, Ramsay M, and Ladhani S
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Databases, Factual, England epidemiology, Female, Hospitalization, Humans, Incidence, Infant, Logistic Models, Male, Medical Record Linkage, Meningococcal Infections diagnosis, Meningococcal Infections prevention & control, Meningococcal Vaccines, Middle Aged, Neisseria meningitidis isolation & purification, Polymerase Chain Reaction, Risk Factors, Sepsis microbiology, Young Adult, Meningococcal Infections epidemiology, Meningococcal Infections microbiology
- Abstract
Background: Invasive meningococcal disease (IMD) is rare but remains one of the most feared infectious diseases worldwide. We linked multiple national datasets to describe disease characteristics and outcomes of IMD in England over a five-year period., Methods: IMD cases confirmed by Public Health England (2007-11) were linked with national hospitalisation records and death registrations. Cases were analysed by age, gender, capsular group, clinical presentation, diagnostic test and outcome. Risk factors for death were assessed using multivariable logistic regression., Results: Overall, 4619 of 5115 (90.30%) laboratory-confirmed IMD cases were successfully linked to a hospitalisation record. Group B meningococci were responsible for 87.33% (n = 4034) of hospitalised IMD cases, ranging from 93.56% (2294/2452) in <15 year-old to 53.52% (152/284) among ≥65 year-old. Most cases presented with meningitis only (n = 2057, 44.53%), septicaemia only (n = 1725, 37.35%) or both meningitis and septicaemia (n = 389, 8.42%). Over half the cases (2526/4619, 54.69%) were confirmed by PCR only, 22.91% (1058/4619) by culture only and 22.41% (1035/4619) by both. The case fatality rate was 4.46% (206/4619; 95% CI, 3.88-5.10%) and varied by age, clinical presentation and capsular group. Children under 15 years who died within 30 days of diagnosis were significantly more likely to have been diagnosed by culture than by PCR alone (OR, 1.56; 95% CI, 1.02-2.39; P = 0.040)., Conclusions: We identified complex interactions between age, meningococcal capsular group, clinical presentation, diagnostic method and death. The recent introduction of two new meningococcal immunisation programmes in the UK should significantly reduce IMD cases and deaths in the coming years., (Copyright © 2016. Published by Elsevier Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
43. Meningococcal Group W Disease in Infants and Potential Prevention by Vaccination.
- Author
-
Parikh SR, Campbell H, Beebeejaun K, Ribeiro S, Gray SJ, Borrow R, Ramsay ME, and Ladhani SN
- Subjects
- England epidemiology, Humans, Infant, Meningococcal Infections epidemiology, Meningococcal Infections immunology, Neisseria meningitidis immunology, Vaccination, Meningococcal Infections microbiology, Meningococcal Infections prevention & control, Meningococcal Vaccines immunology, Neisseria meningitidis classification
- Published
- 2016
- Full Text
- View/download PDF
44. The Interleukin-1 Balance During Encephalitis Is Associated With Clinical Severity, Blood-Brain Barrier Permeability, Neuroimaging Changes, and Disease Outcome.
- Author
-
Michael BD, Griffiths MJ, Granerod J, Brown D, Keir G, Wnęk M, Cox DJ, Vidyasagar R, Borrow R, Parkes LM, and Solomon T
- Subjects
- Albumins cerebrospinal fluid, Cohort Studies, Encephalitis, Herpes Simplex blood, Encephalitis, Herpes Simplex cerebrospinal fluid, England, Glasgow Coma Scale, Humans, Interleukin 1 Receptor Antagonist Protein blood, Interleukin 1 Receptor Antagonist Protein cerebrospinal fluid, Interleukin-1 blood, Interleukin-1 cerebrospinal fluid, Interleukin-10 blood, Interleukin-10 cerebrospinal fluid, Interleukin-1beta blood, Interleukin-1beta cerebrospinal fluid, Magnetic Resonance Imaging, Neuroimaging, Prospective Studies, Serum Albumin analysis, Simplexvirus immunology, Temporal Lobe pathology, Blood-Brain Barrier, Capillary Permeability, Encephalitis, Herpes Simplex immunology, Inflammation Mediators blood, Inflammation Mediators cerebrospinal fluid, Interleukin-1 metabolism
- Abstract
Background: Encephalitis is parenchymal brain inflammation, commonly due to herpes simplex virus (HSV). Key host inflammatory mediators and their relationship to blood-brain barrier (BBB) permeability, neuroimaging changes, and disease outcome are poorly understood., Methods: We measured levels of 38 mediators in serum (n = 78) and cerebrospinal fluid (n = 37) specimens from patients with encephalitis, including 17 with disease due to HSV infection. Outcome measures were Glasgow coma and outcome scores; CSF to serum albumin ratio, reflecting BBB permeability; and, in patients with HSV infection, magnetic resonance imaging-based temporal lobe volume., Results: Serum interleukin 1 receptor antagonist (IL-1RA) levels were elevated in patients with a good outcome (P= .004). Among patients infected with HSV, the ratio of CSF IL-1β to IL-1RA was associated with a worse outcome (P= .009); a ratio of ≥0.55 pg/mL had high specificity and sensitivity for a poor outcome (100% and 83%;P= .015). Temporal lobe volume had a negative correlation with serum IL-1RA level (P= .012) and a positive correlation with serum IL-1α level (P= .0003) and CSF IL-1β level (P= .007). A normal coma score was associated with an elevated interleukin 10 (IL-10) level in serum specimens from HSV-infected patients (P= .007) and CSF specimens from all patients (P= .016); the IL-10 level correlated inversely with BBB permeability (P= .005)., Conclusions: A proinflammatory cytokine response is associated with greater clinical severity, BBB permeability, and neuroimaging damage during encephalitis. IL-1 antagonists should be investigated as adjunctive treatment in encephalitis., (© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
45. HPV Serology Testing Confirms High HPV Immunisation Coverage in England.
- Author
-
Mesher D, Stanford E, White J, Findlow J, Warrington R, Das S, Pebody R, Borrow R, and Soldan K
- Subjects
- Adolescent, Child, England epidemiology, Female, Humans, Papillomavirus Infections immunology, Papillomavirus Infections virology, Young Adult, Human papillomavirus 16 immunology, Human papillomavirus 18 immunology, Immunization, Papillomavirus Infections blood, Papillomavirus Infections diagnosis, Papillomavirus Vaccines immunology
- Abstract
Background: Reported human papillomavirus (HPV) vaccination coverage in England is high, particularly in girls offered routine immunisation at age 12 years. Serological surveillance can be used to validate reported coverage and explore variations within it and changes in serological markers over time., Methods: Residual serum specimens collected from females aged 15-19 years in 2010-2011 were tested for anti-HPV16 and HPV18 IgG by ELISA. Based on these results, females were classified as follows: seronegative, probable natural infection, probable vaccine-induced seropositivity, or possible natural infection/possible vaccine-induced seropositivity. The proportion of females with vaccine-induced seropositivity was compared to the reported vaccination coverage., Results: Of 2146 specimens tested, 1380 (64%) were seropositive for both types HPV16 and HPV18 and 159 (7.4%) positive for only one HPV type. The IgG concentrations were far higher for those positive for both HPV types than those positive for only one HPV type. 1320 (62%) females were considered to have probable vaccine-induced seropositivity. Among vaccine-induced seropositives, antibody concentrations declined with increasing age at vaccination and increasing time since vaccination., Conclusions: The proportion of females with vaccine-induced seropositivity was closest to the reported 3-dose coverage in those offered the vaccination at younger ages, with a greater discrepancy in the older females. This suggests either some under-reporting of immunisations of older females and/or that partial vaccination (i.e. one- or two-doses) has provided high antibody responses in 13-17 year olds.
- Published
- 2016
- Full Text
- View/download PDF
46. Variations in Neisseria meningitidis carriage by socioeconomic status: a cross-sectional study.
- Author
-
Cleary PR, Calvert N, Gee S, Graham C, Gray S, Kaczmarski E, Morphet J, Murphy L, Verlander N, Wood T, and Borrow R
- Subjects
- Adolescent, Adult, Age Factors, Child, Child, Preschool, Cross-Sectional Studies, England epidemiology, Female, Humans, Logistic Models, Male, Middle Aged, Prevalence, Risk Factors, Sex Factors, Social Class, Social Determinants of Health statistics & numerical data, Young Adult, Carrier State epidemiology, Meningococcal Infections epidemiology, Neisseria meningitidis
- Abstract
Background: Deprivation is associated with an increased risk of invasive Neisseria meningitidis disease, but little is known about the relationship between deprivation and asymptomatic carriage of N. meningitidis. This analysis was conducted to examine the relationship between meningococcal carriage and deprivation., Methods: As part of a rapid meningococcal carriage prevalence study conducted in West Cumbria to investigate an apparent cluster of invasive meningococcal disease, data were collected on lifestyle and social factors, including area-level indicators of socioeconomic status, to identify factors associated with meningococcal carriage., Results: In a multivariable log binomial regression model adjusted for age, lower socioeconomic status was significantly associated with higher prevalence of meningococcal carriage. A 1-unit increase in Index of Multiple Deprivation (2010) score was associated with a 1.7% increase in meningococcal carriage prevalence (95% confidence interval 0.3-3.0%). Age was the only significant predictor of carriage of Neisseria lactamica., Conclusions: Living in a deprived area is associated with increased carriage of Group B meningococcus. Deprivation is an important factor to consider in the evaluation of the effectiveness and cost-effectiveness of the introduction of new meningococcal B vaccines and the development and implementation of immunization policies. Further work is required to understand whether deprivation has an effect on meningococcal carriage through other factors such as smoking., (© Crown copyright 2015.)
- Published
- 2016
- Full Text
- View/download PDF
47. Characteristic Cytokine and Chemokine Profiles in Encephalitis of Infectious, Immune-Mediated, and Unknown Aetiology.
- Author
-
Michael BD, Griffiths MJ, Granerod J, Brown D, Davies NW, Borrow R, and Solomon T
- Subjects
- Adult, Bacterial Infections blood, Bacterial Infections cerebrospinal fluid, Biomarkers, Cell Adhesion Molecules blood, Cell Adhesion Molecules cerebrospinal fluid, Chemokines cerebrospinal fluid, Chemokines classification, Diagnosis, Differential, Encephalitis etiology, Encephalitis immunology, Encephalitis, Viral blood, Encephalitis, Viral cerebrospinal fluid, Encephalitis, Viral diagnosis, England epidemiology, Female, Humans, Infectious Encephalitis blood, Infectious Encephalitis cerebrospinal fluid, Infectious Encephalitis diagnosis, Leukocyte Count, Male, Multicenter Studies as Topic, Mycoses blood, Mycoses cerebrospinal fluid, Mycoses diagnosis, Paraneoplastic Syndromes, Nervous System blood, Paraneoplastic Syndromes, Nervous System cerebrospinal fluid, Paraneoplastic Syndromes, Nervous System diagnosis, Peroxidase blood, Peroxidase cerebrospinal fluid, Retrospective Studies, Toxoplasmosis, Cerebral blood, Toxoplasmosis, Cerebral cerebrospinal fluid, Toxoplasmosis, Cerebral diagnosis, Cytokines blood, Cytokines cerebrospinal fluid, Encephalitis blood, Encephalitis cerebrospinal fluid
- Abstract
Background: Encephalitis is parenchymal brain inflammation due to infectious or immune-mediated processes. However, in 15-60% the cause remains unknown. This study aimed to determine if the cytokine/chemokine-mediated host response can distinguish infectious from immune-mediated cases, and whether this may give a clue to aetiology in those of unknown cause., Methods: We measured 38 mediators in serum and cerebrospinal fluid (CSF) of patients from the Health Protection Agency Encephalitis Study. Of serum from 78 patients, 38 had infectious, 20 immune-mediated, and 20 unknown aetiology. Of CSF from 37 patients, 20 had infectious, nine immune-mediated and eight unknown aetiology., Results: Heat-map analysis of CSF mediator interactions was different for infectious and immune-mediated cases, and that of the unknown aetiology group was similar to the infectious pattern. Higher myeloperoxidase (MPO) concentrations were found in infectious than immune-mediated cases, in serum and CSF (p = 0.01 and p = 0.006). Serum MPO was also higher in unknown than immune-mediated cases (p = 0.03). Multivariate analysis selected serum MPO; classifying 31 (91%) as infectious (p = 0.008) and 17 (85%) as unknown (p = 0.009) as opposed to immune-mediated. CSF data also selected MPO classifying 11 (85%) as infectious as opposed to immune-mediated (p = 0.036). CSF neutrophils were detected in eight (62%) infective and one (14%) immune-mediated cases (p = 0.004); CSF MPO correlated with neutrophils (p<0.0001)., Conclusions: Mediator profiles of infectious aetiology differed from immune-mediated encephalitis; and those of unknown cause were similar to infectious cases, raising the hypothesis of a possible undiagnosed infectious cause. Particularly, neutrophils and MPO merit further investigation.
- Published
- 2016
- Full Text
- View/download PDF
48. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016.
- Author
-
Campbell H, Parikh SR, Borrow R, Kaczmarski E, Ramsay ME, and Ladhani SN
- Subjects
- Abdominal Pain microbiology, Adolescent, Arthritis, Infectious microbiology, England, Fatal Outcome, Female, Humans, Male, Meningococcal Infections microbiology, Neisseria meningitidis genetics, Neisseria meningitidis isolation & purification, Pneumonia, Bacterial microbiology, Retrospective Studies, Sepsis microbiology, Young Adult, Abdominal Pain etiology, Diarrhea etiology, Meningococcal Infections diagnosis, Neisseria meningitidis classification, Vomiting etiology
- Abstract
Atypical clinical presentations associated with group W meningococcal disease (MenW) are well-described and include pneumonia, septic arthritis, endocarditis and epiglottitis/supraglottitis. Following anecdotal reports of teenagers presenting with predominantly gastrointestinal symptoms, we undertook a case review of MenW cases in 15 to 19 year-olds diagnosed in England between July 2015 and January 2016. Of the 15 cases, seven presented with a short history of nausea, vomiting and diarrhoea; five of these seven cases died within 24 hours of presentation to hospital.
- Published
- 2016
- Full Text
- View/download PDF
49. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
- Author
-
Ladhani SN, Andrews NJ, Southern J, Jones CE, Amirthalingam G, Waight PA, England A, Matheson M, Bai X, Findlow H, Burbidge P, Thalasselis V, Hallis B, Goldblatt D, Borrow R, Heath PT, and Miller E
- Subjects
- Antigens, Bacterial immunology, Cohort Studies, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, England, Female, Haemophilus Vaccines administration & dosage, Haemophilus Vaccines immunology, Humans, Immunization, Secondary, Immunoglobulin G blood, Infant, Male, Meningococcal Vaccines administration & dosage, Pneumococcal Vaccines administration & dosage, Pneumococcal Vaccines immunology, Poliovirus Vaccine, Inactivated administration & dosage, Pregnancy, Tetanus Toxoid administration & dosage, Tetanus Toxoid immunology, Vaccines, Conjugate administration & dosage, Vaccines, Conjugate immunology, Whooping Cough prevention & control, Antibodies, Bacterial blood, Bordetella pertussis immunology, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Immunity, Maternally-Acquired, Whooping Cough immunology
- Abstract
Introduction: In England, antenatal pertussis immunization using a tetanus/low-dose diphtheria/5-component acellular-pertussis/inactivated-polio (TdaP5/IPV) vaccine was introduced in October 2012. We assessed infant responses to antigens in the maternal vaccine and to those conjugated to tetanus (TT) or the diphtheria toxin variant, CRM., Methods: Infants of 141 TdaP5/IPV-vaccinated mothers in Southern England immunized with DTaP5/IPV/Haemophilus influenzae b (Hib-TT) vaccine at 2-3-4 months, 13-valent pneumococcal vaccine (PCV13, CRM-conjugated) at 2-4 months and 1 or 2 meningococcal C vaccine (MCC-CRM- or MCC-TT) doses at 3-4 months had blood samples taken at 2 and/or 5 months of age., Results: Antibody responses to pertussis toxin (PT), filamentous hemagglutinin (FHA), fimbriae 2 + 3 (FIMs), diphtheria, tetanus, Hib, MCC and PCV13 serotypes were compared to responses in a historical cohort of 246 infants born to mothers not vaccinated in pregnancy. Infants had high pertussis antibody concentrations pre-immunization but only PT antibodies increased post-immunization (fold-change, 2.64; 95% confidence interval [CI], 2.12-3.30; P < .001), whereas FHA antibodies fell (fold-change, 0.56; 95% CI, .48-.65; P < .001). Compared with infants of unvaccinated mothers, PT, FHA, and FIMs antibodies were lower post-vaccination, with fold-differences of 0.67 (0.58-0.77; P < .001), 0.62 (0.54-0.71; P < .001) and 0.51 (0.42-0.62; P < .001), respectively. Antibodies to diphtheria and some CRM-conjugated antigens were also lower, although most infants achieved protective thresholds; antibodies to tetanus and Hib were higher., Conclusions: Antenatal pertussis immunization results in high infant pre-immunization antibody concentrations, but blunts subsequent responses to pertussis vaccine and some CRM-conjugated antigens. In countries with no pertussis booster until school age, continued monitoring of protection against pertussis is essential., (© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
50. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study.
- Author
-
Hill DM, Lucidarme J, Gray SJ, Newbold LS, Ure R, Brehony C, Harrison OB, Bray JE, Jolley KA, Bratcher HB, Parkhill J, Tang CM, Borrow R, and Maiden MC
- Subjects
- Adolescent, Adult, Age Factors, Aged, Child, Child, Preschool, England epidemiology, Epidemiological Monitoring, Female, Genomic Library, Genotype, Humans, Incidence, Infant, Male, Meningitis, Meningococcal immunology, Meningitis, Meningococcal microbiology, Meningitis, Meningococcal prevention & control, Meningococcal Infections immunology, Meningococcal Infections microbiology, Meningococcal Infections prevention & control, Meningococcal Vaccines administration & dosage, Middle Aged, Molecular Epidemiology, Neisseria meningitidis classification, Neisseria meningitidis immunology, Phylogeny, Serogroup, Vaccination, Wales epidemiology, Genome, Bacterial, Meningitis, Meningococcal epidemiology, Meningococcal Infections epidemiology, Neisseria meningitidis genetics
- Abstract
Background: Invasive meningococcal disease (IMD) is a worldwide health issue that is potentially preventable with vaccination. In view of its sporadic nature and the high diversity of Neisseria meningitidis, epidemiological surveillance incorporating detailed isolate characterisation is crucial for effective control and understanding the evolving epidemiology of IMD. The Meningitis Research Foundation Meningococcus Genome Library (MRF-MGL) exploits whole-genome sequencing (WGS) for this purpose and presents data on a comprehensive and coherent IMD isolate collection from England and Wales via the internet. We assessed the contribution of these data to investigating IMD epidemiology., Methods: WGS data were obtained for all 899 IMD isolates available for England and Wales in epidemiological years 2010-11 and 2011-12. The data had been annotated at 1720 loci, analysed, and disseminated online. Information was also available on meningococcal population structure and vaccine (Bexsero, GlaxoSmithKline, Brentford, Middlesex, UK) antigen variants, which enabled the investigation of IMD-associated genotypes over time and by patients' age groups. Population genomic analyses were done with a hierarchical gene-by-gene approach., Findings: The methods used by MRF-MGL efficiently characterised IMD isolates and information was provided in plain language. At least 20 meningococcal lineages were identified, three of which (hyperinvasive clonal complexes 41/44 [lineage 3], 269 [lineage 2], and 23 [lineage 23]) were responsible for 528 (59%) of IMD isolates. Lineages were highly diverse and showed evidence of extensive recombination. Specific lineages were associated with IMD in particular age groups, with notable diversity in the youngest and oldest individuals. The increased incidence of IMD from 1984 to 2010 in England and Wales was due to successive and concurrent epidemics of different lineages. Genetically, 74% of isolates were characterised as encoding group B capsules: 16% group Y, 6% group W, and 3% group C. Exact peptide matches for individual Bexsero vaccine antigens were present in up to 26% of isolates., Interpretation: The MRF-MGL represents an effective, broadly applicable model for the storage, analysis, and dissemination of WGS data that can facilitate real-time genomic pathogen surveillance. The data revealed information crucial to effective deployment and assessment of vaccines against N meningitidis., Funding: Meningitis Research Foundation, Wellcome Trust, Public Health England, European Union., (Copyright © 2015 Hill et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.